Amide derivative regulator as well as preparation method and application thereof
By designing a new amide derivative compound, the problem of non-selectivity of existing PI3Kα inhibitors on wild type is solved, which significantly improves the inhibition of PI3Kα mutant, reduces side effects, and improves the efficacy of tumor treatment and Security.
Patent Information
- Application Number
- CN202410579689.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-10-30
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing PI3Kα inhibitors have no selectivity to PI3Kα wild type, resulting in severe hyperglycemia side effects, which limits the dosage and efficacy of clinical medicines and affects the therapeutic effect of PI3Kα mutant tumors.
A new amide derivative compound is developed to improve the selectivity of PI3Kα mutant through specific structural design, reduce the inhibition of PI3Kβ/γ/δ, thereby reducing side effects and improving therapeutic effects.
This compound significantly improves the inhibitory properties of PI3Kα mutant, reduces the inhibitory properties of PI3Kβ/γ/δ, reduces the side effects of hyperglycemia, and improves the efficacy and safety of tumor treatment.
Smart Images

Figure CN118930527A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to an amide derivative regulator and a preparation method and application thereof. Background Art
[0002] The phosphatidylinositol 3-kinase (PI3K) protein family is divided into four major categories: I, II, III, and IV, and is involved in the regulation of various cell functions such as cell growth, proliferation, differentiation, survival, and energy metabolism. The four types of PI3K proteins have different structures and functions. The most widely studied is the type I PI3K, which is further divided into four subtypes: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ. Among them, PI3Kα undergoes activation mutations and amplification in many tumors, which is closely related to the occurrence and development of tumors. There are reports that PI3Kβ can activate platelets and play an important role in the occurrence and development of diseases such as thrombosis. PI3Kδ and PI3Kγ are mainly expressed in the blood system and are closely related to the occurrence of the immune system and inflammation. In addition, PI3Kγ is also closely related to blood pressure stability and smooth muscle contraction.
[0003] PI3Kα is composed of the p110α catalytic subunit and the p85 regulatory subunit. The p110α subunit is encoded by the PIK3CA gene. When PI3Kα is regulated by upstream receptor tyrosine kinases (such as insulin receptors, platelet-derived growth factor receptors, etc.) and Ras proteins, it catalyzes phosphatidylinositol 2-phosphate (PIP2) to generate phosphatidylinositol 3-phosphate (PIP3) after activation. PIP3 can further activate protein kinase B (also known as AKT) and its downstream signaling pathways, thereby regulating cell differentiation, migration, and metabolic homeostasis. PI3Kα mutation or amplification can lead to continuous activation of the AKT pathway, rapid cell proliferation, and the occurrence of tumors. PI3Kα is also a key protein in the insulin / insulin receptor pathway, which can regulate the balance of sugar metabolism in tissues such as the liver and skeletal muscle. Inhibition of PI3Kα can lead to reduced liver glycogen synthesis, increased blood sugar, and increased insulin levels in the body.
[0004] PI3Kα is one of the kinases with the highest mutation rate in cancer, with a total mutation rate of 14% in all cancers, and is widely distributed, such as breast cancer, head and neck cancer, ovarian cancer, gastric cancer, head and neck cancer and other cancers. There are various types of PIK3CA gene mutations, among which the three most common hotspot mutations are H1047R mutation (kinase region), E542K (helical region) and E545K (helical region). Currently, clinical PI3Kα inhibitors have strong inhibitory activity against PI3Kα mutants, non-selective inhibition of PI3Kα wild-type, and certain inhibition of PI3Kβ / γ / δ, resulting in the occurrence of severe hyperglycemia side effects mediated by PI3Kα wild-type and side effects such as rash and diarrhea involving the PI3K / AKT pathway in clinical trials. In addition, due to the increase of insulin in the body, the insulin receptor pathway is activated, resulting in enhanced activation of the PI3K pathway, which in turn affects the efficacy of PI3Kα inhibitors. Novartis' Alpelisib (BYL-719) is the fastest-progressing PI3Kα inhibitor and has been approved for combination with Fulvestrant for the treatment of ER with PIK3CA mutations. + HER2 - Breast cancer: The efficacy is good, but the side effect of clinical hyperglycemia is more serious. In addition, HER2 + Clinical trials for breast cancer, triple-negative breast cancer, ovarian cancer, etc. Roche's PI3Kα inhibitor GDC-0077 is in Phase III clinical trials and is indicated for combined treatment of ER with PIK3CA mutations. + HER2 - For breast cancer, the early clinical effect is good, but there are also more serious side effects of hyperglycemia.
[0005] In summary, PI3Kα inhibitors have significant therapeutic effects in indications such as breast cancer and have good market prospects. Existing PI3Kα inhibitors have no selectivity for wild-type PI3Kα, which leads to serious side effects of hyperglycemia and limits clinical dosage and efficacy. Therefore, the development of PI3Kα mutation-specific allosteric inhibitors is of great significance. At present, there are two PI3Kα mutant allosteric inhibitors in the preclinical development stage abroad, namely Relay's RLY-2608 and Eli Lilly's LOXO-783. Both inhibitors have improved the selectivity for wild-type PI3Kα and are very selective for PI3Kβ / γ / δ. They are expected to reduce toxicity and improve efficacy. Clinical trials will be launched in 2022 and have good development prospects. Summary of the invention
[0006] The object of the present invention is to provide a compound represented by general formula (I), its stereoisomers or pharmaceutically acceptable salts thereof:
[0007]
[0008] in:
[0009] is a single bond or a double bond;
[0010] M1 and M2 are each independently selected from a bond, CR 11 NR 11 , CR 22 R 33 , O or S;
[0011] L1 is selected from a bond, NR 44 NR 44 C(O)NR 55 NR 44 C(O)NR 55 (CR 66 R 77 ) n1 NR 44 S(O) n1 NR 55 NR 44 PR 66 (O) n1 NR 55 NR 44 C(=NR 77 )NR 55 、OC(O)NR 55 NR 44 C(O)O、NR 44 C(=S)NR 55 NR 44 C(O) n1 (CR 55 R 66 ) n2 NR 44 (C 3-8 Cycloalkyl)(NR 55 ) n2 ,(NR 55 ) n2 NR 44 (3-8 membered heterocyclic group)(NR 55 ) n2 NR 44 (C 6-10 Aryl)(NR 55 ) n2 NR 44 (5-8 membered heteroaryl)(NR 55 ) n2 NR 44 C(O) n1 (CR 55 R 66 )NR 77 、C(O)NR 44 NR55 C(O), C(O)NR 44 (CR 55 R 66 )C(O)NR 77 or NR 44 (CR 55 R 66 )C(O)NR 77 ;
[0012] Ring A and Ring B are each independently selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0013] R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0014] R2 is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 1-6 Alkylthio, C 1-6 Halogenated alkylthio, halogenated thio, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0015] Alternatively, any two R2 are linked to the adjacent carbon atoms to form a C 3-12 Cycloalkyl or 3-12 membered heterocyclic group, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl; R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0016] R 11 , R 22 or R 33is present or absent, and when present is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -C(O)R 1a 、-NR 2a C(O)R 3a or -C(R 1a R 2a ) t1 R 3a , optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0017] R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0018] Or, R 44 , R 55 , R 66 or R 77 Any two of them are linked to the adjacent carbon atoms to form a C 3-12Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0019] Alternatively, =N on L1 is linked to an atom on ring B to form a 3-12 membered heterocyclic group or a 5-12 membered heteroaryl group, which is optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0020] R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0021] R 1a , R 2a or R 3a are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0022] R aa , R bb or R cc are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0023] t1 is 0, 1, or 2;
[0024] m is 0, 1 or 2;
[0025] n is 0, 1 or 2;
[0026] p is 0, 1, or 2;
[0027] r is 1 or 2;
[0028] n1 is 0, 1 or 2;
[0029] n2 is 0, 1 or 2;
[0030] n3 is 0, 1 or 2; and
[0031] m1 is 0, 1, or 2.
[0032] In a preferred embodiment of the present invention,
[0033] is a single bond or a double bond;
[0034] M1 and M2 are each independently selected from a bond, CR 11 NR 11 , CR 22 R 33 , O or S;
[0035] L1 is selected from a bond, NR 44 NR 44 C(O)NR 55 NR 44 C(O)NR 55 (CR 66 R 77 ) n1 NR 44 S(O) n1 NR 55 NR 44 PR 66 (O) n1 NR 55 NR 44 C(=NR 77 )NR 55 、OC(O)NR 55 NR 44 C(O)O、NR 44 C(=S)NR 55 NR 44 C(O) n1 (CR 55 R 66 ), NR 44 (C 3-8 Cycloalkyl)(NR 55 ) n2 ,(NR 55 ) n2 NR 44 (3-8 membered heterocyclic group)(NR 55 ) n2 NR 44 (C 6-10 Aryl)(NR 55 ) n2 NR 44 (5-8 membered heteroaryl)(NR 55 ) n2 or NR 44 C(O) n1 (CR 55 R 66 )NR 55 ;
[0036] Ring A and Ring B are each independently selected from C3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0037] R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0038] R2 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-6 Alkyl, C 1-6Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0039] Alternatively, any two R2 are linked to the adjacent carbon atoms to form a C 3-12 Cycloalkyl or 3-12 membered heterocyclic group, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl; R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0040] R 11 , R 22 or R 33 is present or absent, and when present is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12Aryl, 5-12 membered heteroaryl, -C(O)R 1a 、-NR 2a C(O)R 3a or -C(R 1a R 2a ) t1 R 3a , optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0041] R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0042] Or, R 44 , R 55 , R 66 or R 77 Any two of them are linked to the adjacent carbon atoms to form a C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0043] Alternatively, =N on L1 is linked to an atom on ring B to form a 3-12 membered heterocyclic group or a 5-12 membered heteroaryl group, which is optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0044] R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0045] R 1a , R 2a or R 3a are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0046] R aa , R bb or R cc are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0047] t1 is 0, 1, or 2;
[0048] m is 0, 1 or 2;
[0049] n is 0, 1 or 2;
[0050] p is 0, 1, or 2;
[0051] r is 1 or 2;
[0052] n1 is 0, 1 or 2;
[0053] n2 is 0, 1 or 2;
[0054] n3 is 0, 1 or 2; and
[0055] m1 is 0, 1, or 2.
[0056] In certain embodiments of the present invention,
[0057] is a single bond or a double bond;
[0058] M1 and M2 are each independently selected from a bond, NR 11 , CR 22 R 33 , O or S;
[0059] L1 is selected from a bond, NR 44 NR 44 C(O)NR 55 NR 44 S(O) n1 NR55 NR 44 PR 66 (O) n1 NR 55 NR 44 C(=NR 77 )NR 55 、OC(O)NR 55 NR 44 C(O)O、NR 44 C(=S)NR 55 NR 44 C(O) n1 (CR 55 R 66 ), NR 44 (C 5-8 Cycloalkyl)(NR 55 ) n2 ,(NR 55 ) n2 NR 44 (5-8 membered heterocyclic group)(NR 55 ) n2 NR 44 (C 6-10 Aryl)(NR 55 ) n2 NR 44 (5-8 membered heteroaryl)(NR 55 ) n2 or NR 44 C(O) n1 (CR 55 R 66 )NR 55 ;
[0060] Ring A and Ring B are each independently selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0061] R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0062] R2 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0063] R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -(CH2) n3 C(O)R31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 or -(CH2) n3 S(O) m1 R 32 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0064] R 11 , R 22 or R 33 is present or absent, and when present is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0065] R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0066] Or, R 55 , R 66 Linked to the carbon atom to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0067] Alternatively, =N on L1 is linked to an atom on ring B to form a 3-12 membered heterocyclic group or a 5-12 membered heteroaryl group, which is optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0068] R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0069] m is 0, 1 or 2;
[0070] n is 0, 1 or 2;
[0071] p is 0, 1, or 2;
[0072] r is 1 or 2;
[0073] n1 is 0, 1 or 2;
[0074] n2 is 0, 1 or 2;
[0075] n3 is 0, 1 or 2; and
[0076] m1 is 0, 1, or 2.
[0077] In certain embodiments of the present invention,
[0078] is a single bond or a double bond;
[0079] M1 and M2 are each independently selected from a bond, NR 11 , CR 22 R 33 , O or S;
[0080] L1 is selected from NR44 NR 44 C(O)NR 55 NR 44 S(O) n1 NR 55 NR 44 PR 66 (O) n1 NR 55 NR 44 C(=NR 77 )NR 55 、OC(O)NR 55 NR 44 C(O)O、NR 44 C(=S)NR 55 NR 44 C(O) n1 (CR 55 R 66 ), NR 44 (C 5-8 Cycloalkyl)(NR 55 ) n2 ,(NR 55 ) n2 NR 44 (5-8 membered heterocyclic group)(NR 55 ) n2 NR 44 (C 6-10 Aryl)(NR 55 ) n2 or NR 44 (5-8 membered heteroaryl)(NR 55 ) n22 ;
[0081] Ring A and Ring B are each independently selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0082] R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0083] R2 is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0084] R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -(CH2) n3 C(O)R31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 or -(CH2) n3 S(O) m1 R 32 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0085] R 11 , R 22 or R 33 is present or absent, and when present is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0086] R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0087] Or, R 55 , R 66 Linked to the carbon atom to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0088] Alternatively, =N on L1 is linked to an atom on ring B to form a 3-12 membered heterocyclic group or a 5-12 membered heteroaryl group, which is optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0089] R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0090] m is 0, 1 or 2;
[0091] n is 0, 1 or 2;
[0092] p is 0, 1, or 2;
[0093] r is 1 or 2;
[0094] n1 is 0, 1 or 2;
[0095] n2 is 0, 1 or 2;
[0096] n3 is 0, 1 or 2; and
[0097] m1 is 0, 1, or 2.
[0098] In certain embodiments of the present invention,
[0099] is a single bond or a double bond;
[0100] M1 and M2 are each independently selected from a bond, NR 11 , CR 22 R 33 , O or S;
[0101] L1 is selected from NR44 C(O)NR 55 NR 44 S(O) n1 NR 55 NR 44 PR 66 (O) n1 NR 55 NR 44 C(=NR 77 )NR 55 、OC(O)NR 55 NR 44 C(O)O、NR 44 C(=S)NR 55 or NR 44 (5-8 membered heteroaryl)(NR 55 ) n2 ;
[0102] Ring A and Ring B are each independently selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0103] R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0104] R2 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0105] R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -(CH2) n3 C(O)R 31 or -(CH2) n3 S(O) m1 R 32 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0106] R 11 , R 22 or R 33 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0107] R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0108] Alternatively, =N on L1 is linked to an atom on ring B to form a 3-12 membered heterocyclic group or a 5-12 membered heteroaryl group, which is optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0109] R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0110] m is 0, 1 or 2;
[0111] n is 0, 1 or 2;
[0112] p is 0, 1, or 2;
[0113] r is 1 or 2;
[0114] n1 is 0, 1 or 2;
[0115] n2 is 0, 1 or 2;
[0116] n3 is 0, 1 or 2; and
[0117] m1 is 0, 1, or 2.
[0118] In a preferred embodiment of the present invention, the compound of formula (I) is further represented by formula (IA-1) or (IA-2):
[0119]
[0120] R1, R2, R3, L1, M1, M2, R 11 , Ring A, Ring B, m, p and r are as defined in the general formula (I).
[0121] In a further preferred embodiment of the present invention, the compound of general formula (I) is further represented by general formula (IB):
[0122]
[0123] Ring B is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl is substituted with one or more substituents;
[0124] Ring C is selected from C 5-8 Cycloalkyl, 5-8 membered heterocyclic group, C 6-10 Aryl or 5-8 membered heteroaryl, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl, substituted by one or more substituents; ring C is preferably C 5-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, which may be further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 The aryl or 5-10 membered heteroaryl is substituted with one or more substituents.
[0125] In certain embodiments of the present invention, ring C is selected from C 5-10 Aryl or 5-8 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl, substituted by one or more substituents; ring C is preferably C 5-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, which may be further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl is substituted with one or more substituents;
[0126] In certain embodiments of the present invention, Ring B is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl is substituted with one or more substituents;
[0127] Ring C is selected from C 5-8 Cycloalkyl, 5-8 membered heterocyclic group, C 6-10 Aryl or 5-8 membered heteroaryl, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl, substituted by one or more substituents; ring C is preferably C 5-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, which may be further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl is substituted with one or more substituents;
[0128] R1, R2, R3, R 11 , R 44 , Ring A, Ring B, m, p and r are as defined in the general formula (I).
[0129] In a further preferred embodiment of the present invention, the compound of general formula (I) is further represented by general formula (IC):
[0130]
[0131] Ring B is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl, wherein one or more substituents are substituted; preferably ring B is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 substituted by one or more substituents of aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S;
[0132] Ring D is selected from 3-12 membered heterocyclic groups or 5-12 membered heteroaryl groups, optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6The ring D is preferably substituted with one or more substituents of a deuterated alkyl group; the ring D preferably contains 1-3 3-10 membered heterocyclic groups selected from N, O or S atoms or 1-3 5-10 membered heteroaryl groups selected from N, O or S atoms, optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0133] R1, R2, R3, R 11 , R 44 , Ring A, m, p and r are as defined in the general formula (I).
[0134] In a further preferred embodiment of the present invention, the compound of general formula (I) is further represented by general formula (IC-1) or (IC-2):
[0135]
[0136] M2 is independently selected from NR 11 , CR 22 R 33 , O or S;
[0137] Ring B1 is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl, wherein one or more substituents are substituted; preferably ring B is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 substituted by one or more substituents of aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S;
[0138] Ring D is selected from 3-12 membered heterocyclic groups or 5-12 membered heteroaryl groups, optionally substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 The ring D is preferably substituted with one or more substituents of a deuterated alkyl group; the ring D preferably contains 1-3 3-10 membered heterocyclic groups selected from N, O or S atoms or 1-3 5-10 membered heteroaryl groups selected from N, O or S atoms, optionally substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0139] R1, R2, R3, R 11 , R 44 , Ring A, m, p and r are as defined in the general formula (IA-1) or (IA-2).
[0140] In certain embodiments of the present invention,
[0141] M2 is independently selected from NR 11 , CR 22 R 33 , O or S;
[0142] Ring B1 is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl, wherein one or more substituents are substituted; preferably ring B is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring B is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 The cycloalkyl group is substituted with one or more substituents selected from N, O or S atoms, 3-6 membered heterocyclic group, phenyl group or 5-8 membered heteroaryl group;
[0143] Ring D is selected from 3-12 membered heterocyclic groups or 5-12 membered heteroaryl groups, optionally substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6The ring D is preferably substituted with one or more substituents of a deuterated alkyl group; the ring D preferably contains 1-3 3-10 membered heterocyclic groups selected from N, O or S atoms or 1-3 5-10 membered heteroaryl groups selected from N, O or S atoms, optionally substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The ring D is preferably substituted with one or more substituents of a deuterated alkyl group; the ring D is more preferably substituted with a 3-8 membered heterocyclic group containing 1-3 selected from N, O or S atoms or a 5-8 membered heteroaryl group containing 1-3 selected from N, O or S atoms, optionally substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0144] When M2 is 0, Not for
[0145] In a further preferred embodiment of the present invention, the compound of general formula (I) is further represented by general formula (IC-11), (IC-12), (IC-13) or (IC-14):
[0146]
[0147] in:
[0148] X1~X 17 Each independently selected from C(O), CR X1 , CR X1 R X2 , N, NR X1 , O or S;
[0149] M3~M 11 Each independently selected from C(O), CR X1 , CR X1 R X2 , N, NR X1 , O or S;
[0150] R X1 or R X2 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0151] M2, R1, R2, R3, R 11 , Ring A, Ring B1, m, p and r are defined as shown in the general formula (IC-1) or (IC-2).
[0152] In a further preferred embodiment of the present invention, the compound of general formula (I) is further represented by general formula (ID) or (ID'):
[0153]
[0154] M2, R1, R2, R3, R 11 , R 44 , R 55 , R 66 , R 77 , Ring A, Ring B, m, p and r are as defined in the general formula (IA-1).
[0155] In a further preferred embodiment of the present invention, the compound of general formula (I) is further represented by general formula (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10) or (ID-14):
[0156]
[0157] M2, R1, R2, R3, R 11 , R 66 , R 77 , Ring A, Ring B, m, p and r are defined as shown in the general formula (IA-1) or (IA-2).
[0158] In a preferred embodiment of the present invention, M2 is independently selected from O or S.
[0159] In a further preferred embodiment of the present invention, the compound of general formula (I) is further represented by general formula (ID-11):
[0160]
[0161] Ring C1 is present or absent, and when present is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0162] R q are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0163] u is 0, 1, 2, or 3.
[0164] In a further preferred embodiment of the present invention, the compound of general formula (I) is further represented by general formula (ID-12):
[0165]
[0166] Two R2 are linked to the adjacent carbon atom to form C 3-10 Cycloalkyl or 3-10 membered heterocyclic group, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 The alkyl group is substituted with one or more substituents;
[0167] Preferably, two R2 are linked to the adjacent carbon atom to form a C 3-8 Cycloalkyl or 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 The alkyl group is substituted with one or more substituents;
[0168] More preferably, two R2 are linked to the adjacent carbon atom to form a C 3-6 Cycloalkyl or 3-6 membered heterocyclic group containing 1-3 N, O or S atoms, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 The alkyl group is substituted with one or more substituents;
[0169] Further preferably, two R2 are linked to the connected carbon atom to form a cyclopropyl, cyclobutyl or cyclopentyl group, which may be further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl;
[0170] M2, R1, R3, R 11 , Ring A, m, and p are as defined in the general formula (ID-1).
[0171] In a further preferred embodiment of the present invention, the compound of general formula (I) is further represented by general formula (ID-13):
[0172]
[0173] M2 are each independently selected from O or S;
[0174] R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 Alkyl, optionally substituted with hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0175] R2 is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 Alkyl, optionally substituted with hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0176] Alternatively, two R2 are linked to the adjacent carbon atom to form a C 3-6 Cycloalkyl or 3-6 membered heterocyclic group containing 1-3 N, O or S atoms, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3Hydroxyalkyl, cyano substituted C 1-3 The alkyl group is substituted with one or more substituents;
[0177] R 11 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl, 5-10 membered heteroaryl containing 1-3 N, O or S atoms, -C(O)R 1a 、-NR 2a C(O)R 3a or -C(R 1a R 2a ) t1 R 3a , optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R 11 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl, 5-8 membered heteroaryl containing 1-3 N, O or S atoms, -C(O)R 1a 、-NR 2a C(O)R 3a or -C(R 1a R 2a ) t1 R 3a , optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C1-3 More preferably, R 11 is selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, propyl, vinyl, allyl, propenyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, propoxy, fluorinated methoxy, fluorinated ethoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl, cyano-substituted methyl, cyano-substituted ethyl, cyano-substituted propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, formyl, acetyl, Optionally substituted with one or more substituents selected from the group consisting of hydrogen, hydroxy, fluorine, chlorine, bromine, cyano, amino, methyl, ethyl, propyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, and difluoromethyl;
[0178] R 1a , R 2a or R 3a are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R 1a , R 2a or R 3a are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl or 5-8 membered heteroaryl containing 1-3 N, O or S atoms, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 More preferably, R 1a , R 2a or R 3a each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, propyl, vinyl, allyl, propenyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, propoxy, fluorine-substituted methoxy, fluorine-substituted ethoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl, cyano-substituted methyl, cyano-substituted ethyl or cyano-substituted propyl;
[0179] R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl, 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 , the C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl, 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl, 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, substituted by one or more substituents;
[0180] Preferably, R3 is each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, propyl, vinyl, allyl, propenyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, propoxy, fluorinated methoxy, fluorinated ethoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl, cyano-substituted methyl, cyano-substituted ethyl, cyano-substituted propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, formyl, acetyl, -CH2C(O)NH2, -CH2S(O)2NH2, -NHC(O)CF3, -P(O)(CH3)2, Optionally substituted with one or more substituents selected from the group consisting of hydrogen, hydroxy, fluorine, chlorine, bromine, cyano, amino, methyl, ethyl, propyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, and difluoromethyl;
[0181] R aa , R bb or R cc are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 Alkyl, optionally substituted with hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0182] Preferably, R aa , R bb or R cceach independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxy, cyano, nitro, methyl, ethyl, propyl, vinyl, allyl, propenyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, propoxy, fluorine-substituted methoxy, fluorine-substituted ethoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl, cyano-substituted methyl, cyano-substituted ethyl or cyano-substituted propyl, optionally substituted with one or more substituents selected from hydrogen, hydroxy, fluorine, chlorine, bromine, cyano, amino, methyl, ethyl, propyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl or difluoromethyl;
[0183] R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0184] More preferably, R 31 or R 32 are each independently selected from deuterium, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, is substituted with one or more substituents;
[0185] The conditions are:
[0186] (1) When M2 is O, R1 is F, R2 is H or trifluoromethyl, and R3 is not -(CR aa R bb ) n3 C(O)R31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 When R 11 Not methyl;
[0187] m and p are as defined in the general formula (ID-1).
[0188] In a further preferred embodiment of the present invention, the compound of general formula (I) is further represented by general formula (IE) or (IE-1):
[0189]
[0190] M2 is selected from NR 11 , CR 22 R 33 , O or S;
[0191] Ring E is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl, wherein one or more substituents are substituted; preferably ring E is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 substituted by one or more substituents of aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S;
[0192] R1, R2, R3, R 11 , R 44 , R 55 , M2, Ring A, Ring B, m, p and r are as defined in the general formula (IA-1) or (IA-2).
[0193] In a further preferred embodiment of the present invention, the compound of formula (IA-1) or (IA-2) is further represented by formula (IF) or (IF-1):
[0194]
[0195] Ring B1 is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl; preferably ring B1 is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring B1 is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 The cycloalkyl group is substituted with one or more substituents selected from N, O or S atoms, 3-6 membered heterocyclic group, phenyl group or 5-8 membered heteroaryl group;
[0196] Ring D is selected from 3-12 membered heterocyclic groups or 5-12 membered heteroaryl groups, optionally substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6The ring D is preferably substituted with one or more substituents of a deuterated alkyl group; the ring D preferably contains 1-3 3-10 membered heterocyclic groups selected from N, O or S atoms or 1-3 5-10 membered heteroaryl groups selected from N, O or S atoms, optionally substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The ring D is preferably substituted with one or more substituents of a deuterated alkyl group; the ring D is more preferably substituted with a 3-8 membered heterocyclic group containing 1-3 selected from N, O or S atoms or a 5-8 membered heteroaryl group containing 1-3 selected from N, O or S atoms, optionally substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0197] R1, R2, R3, M2, m, and p are as defined in the general formula (IA-1) or (IA-2).
[0198] In a further preferred embodiment of the present invention, the compound of formula (ID-10) is further represented by formula (IG) or:
[0199]
[0200] Ring B5 is selected from 3-10 membered heterocyclic groups, which may be further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring B5 is selected from a 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, and optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 More preferably, ring B5 is selected from a 5-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, which may be further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; further preferably, ring B5 is selected from Optionally, it may be further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl;
[0201] R1, R2, R3, M2, R 11 , m, and p are as defined in the general formula (ID-10).
[0202] The present invention also provides a compound represented by general formula (II), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
[0203]
[0204] M2 is selected from NR 11 , O, S or CR 22 R 33 ;
[0205] Ring A2 and Ring B2 are each independently selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0206] Ring C2 is present or absent, and when present is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0207] R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0208] R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0209] R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -(CH2) n4 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n4 C(O)NR 31 R32, -(CH2) n4 P(O)R 31 R 32 、-(CH2) n4 P(O)2R 31 or -(CH2) n4 S(O) m4 R 32 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0210] R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0211] R 11 , R 22 or R 33 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0212] When ring A2 is When , ring B2 is not a benzene ring;
[0213] m2-m4 are each independently 0, 1, 2 or 3; and
[0214] n4 is 0, 1 or 2.
[0215] Ring A3 is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0216] Ring B3 is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0217] Ring C3 is present or absent, and when present is selected from C 3-12Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0218] m5-m8 are each independently 0, 1, 2 or 3; and
[0219] n5 is 0, 1 or 2.
[0220] The present invention also provides a compound represented by general formula (IV), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
[0221]
[0222] in:
[0223] is a single bond or a double bond;
[0224] X1 to X4 are each independently selected from a bond, N, NR x1 , C, CR x1 , CR x1 R x2 , O or S;
[0225] L1 is selected from a bond, NR 44 NR 44 C(O)NR 55 NR 44 S(O) n1 NR 55 NR 44 PR 66 (O) n1 NR 55 NR 44 C(=NR 77 )NR 55 、OC(O)NR 55 NR 44 C(O)O、NR 44 C(=S)NR 55 NR44 C(O) n1 (CR 55 R 66 ), NR 44 (C 5-8 Cycloalkyl)(NR 55 ) n2 ,(NR 55 ) n2 NR 44 (5-8 membered heterocyclic group)(NR 55 ) n2 NR 44 (C 6-10 Aryl)(NR 55 ) n2 NR 44 (5-8 membered heteroaryl)(NR 55 ) n2 or NR 44 C(O) n1 (CR 55 R 66 )NR 77 ;
[0226] Ring A and Ring B are each independently selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0227] R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0228] R2 is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0229] R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -(CH2) n6 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n6 C(O)NR 31 R 32 、-(CH2) n6 P(O)R 31 R 32 、-(CH2) n6 P(O)2R 31 or -(CH2) n6 S(O)m9 R 32 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0230] R x1 or R x2 is present or absent, and when present is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0231] R 44 , R 55 , R 66 or R 77are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0232] Or, R 55 , R 66 Linked to the carbon atom to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0233] Alternatively, =N on L1 is linked to an atom on ring B to form a 3-12 membered heterocyclic group or a 5-12 membered heteroaryl group, which is optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0234] R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0235] m9 is 0, 1, or 2;
[0236] n6 is 0, 1 or 2;
[0237] t is 0, 1, or 2;
[0238] v is 1 or 2; and
[0239] w is 0, 1, or 2.
[0240] In a further preferred embodiment of the present invention, the compound of general formula (IV) is further represented by general formula (IV-1), (IV-2) or (IV-3):
[0241]
[0242] Ring A, Ring B, X1, X2, X3, X4, R1, R2, R3, L1, t, v, or w are as defined in the general formula (IV).
[0243] The present invention also provides a compound represented by general formula (V) or (VI), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
[0244]
[0245] in:
[0246] M2 and M1 are each independently selected from a bond, NR 11 , CR 11 , CR 22 R 33 , O or S;
[0247] L1 is selected from a bond, NR 44 NR 44 C(O)NR 55 NR 44 C(O)NR 55 (CR66 R 77 ) n1 NR 44 S(O) n1 NR 55 NR 44 PR 66 (O) n1 NR 55 NR 44 C(=NR 77 )NR 55 、OC(O)NR 55 NR 44 C(O)O、NR 44 C(=S)NR 55 NR 44 C(O) n1 (CR 55 R 66 ), NR 44 (C 3-8 Cycloalkyl)(NR 55 ) n2 ,(NR 55 ) n2 NR 44 (3-8 membered heterocyclic group)(NR 55 ) n2 NR 44 (C 6-10 Aryl)(NR 55 ) n2 NR 44 (5-8 membered heteroaryl)(NR 55 ) n2 or NR 44 C(O) n1 (CR 55 R 66 )NR 55 ;
[0248] Ring A and Ring B are each independently selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0249] R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0250] R2 is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0251] Alternatively, any two R2 are linked to the adjacent carbon atoms to form a C 3-12 Cycloalkyl or 3-12 membered heterocyclic group, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0252] R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0253] R 11 , R 22 or R 33 is present or absent, and when present is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -C(O)R 1a 、-NR 2a C(O)R 3a or -C(R 1a R 2a ) t1 R 3a , optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0254] R 44 , R55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0255] Or, R 44 , R 55 , R 66 or R 77 Any two of them are linked to the adjacent carbon atoms to form a C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0256] Alternatively, =N on L1 is linked to an atom on ring B to form a 3-12 membered heterocyclic group or a 5-12 membered heteroaryl group, which is optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0257] R 31 or R32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0258] R 1a , R 2a or R 3a are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0259] R aa , R bb or R cc are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0260] t1 is 0, 1, or 2;
[0261] m is 0, 1 or 2;
[0262] n is 0, 1 or 2;
[0263] p is 0, 1, or 2;
[0264] r is 1 or 2;
[0265] n1 is 0, 1 or 2;
[0266] n2 is 0, 1 or 2;
[0267] n3 is 0, 1 or 2; and
[0268] m1 is 0, 1, or 2.
[0269] The present invention also provides a compound represented by general formula (VII), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
[0270]
[0271] in:
[0272] Ring A and Ring B are each independently selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0273] R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0274] R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa Rbb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0275] R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0276] Or, R 44 , R 55 , R 66 or R 77 Any two of them are linked to the adjacent carbon atoms to form a C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents;
[0277] R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0278] R aa , R bb or R cc are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group;
[0279] m is 0, 1 or 2;
[0280] p is 0, 1, or 2;
[0281] m1 is 0, 1 or 2; and
[0282] n3 is 0, 1 or 2.
[0283] In certain embodiments of the present invention,
[0284] R2 are each independently selected from hydrogen, deuterium, C 1-3 Alkylthio, C 1-3 haloalkylthio or halothio, optionally substituted with hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0285] Preferably, R2 is each independently selected from hydrogen, deuterium, methylthio, trifluoromethylthio or fluorothio.
[0286] In certain embodiments of the present invention,
[0287] R2, R 44 or R 55 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 Alkyl, optionally substituted with hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0288] Preferably, R2, R 44 or R 55 each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, propyl, vinyl, allyl, propenyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, propoxy, fluorine-substituted methoxy, fluorine-substituted ethoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl, cyano-substituted methyl, cyano-substituted ethyl, cyano-substituted propyl;
[0289] The condition is that R2, R 44 or R 55 At least one of the groups is a hydroxyl group.
[0290] In a further preferred embodiment of the present invention,
[0291] M1 and M2 are each independently selected from a bond, NR 11 , CR 11 , CR 22 R 33 , O or S;
[0292] R 11 , R 22 or R 33 is present or absent, and when present is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C(O)R 1a 、-NR 2a C(O)R 3a or -C(R 1a R 2a ) t1 R 3a , optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3is substituted with one or more substituents of a deuterated alkyl group;
[0293] Preferably, R 11 , R 22 or R 33 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl, 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, -C(O)R 1a 、-NR 2a C(O)R 3a or -C(R 1a R 2a ) t1 R 3a , which may be further substituted with one or more substituents selected from deuterium, oxo, thioxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl;
[0294] R 1a , R 2a or R 3a are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0295] Preferably, R 1a , R 2a or R 3a are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 The aryl group or the 5-10 membered heteroaryl group containing 1-3 atoms selected from N, O or S atoms may be optionally further substituted by one or more substituents selected from deuterium, oxo, thio, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl.
[0296] In certain embodiments of the present invention, M1 and M2 are each independently selected from a bond, NR 11 , CR 22 R 33 , O or S;
[0297] R 11 , R 22 or R 33 is present or absent, and when present is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R 11 , R 22 or R 33are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or a 5-10 membered heteroaryl group containing 1-3 atoms selected from N, O or S atoms.
[0298] In certain embodiments of the present invention,
[0299] L1 is selected from NR 44 NR 44 C(O)NR 55 NR 44 S(O) n1 NR 55 NR 44 PR 66 (O) n1 NR 55 NR 44 C(=NR 77 )NR 55 、OC(O)NR 55 NR 44 C(O)O、NR 44 C(=S)NR 55 NR 44 C(O) n1 (CR 55 R 66 ) n2 NR 44 (C 5-8 Cycloalkyl)(NR 55 ) n2 ,(NR 55 ) n2 NR 44 (5-8 membered heterocyclic group)(NR 55 ) n2 NR 44 (C 6-10 Aryl)(NR 55 ) n2 NR 44 (5-8 membered heteroaryl)(NR 55 ) n2 NR44 C(O) n1 (CR 55 R 66 )NR 77 、C(O)NR 44 NR 55 C(O), C(O)NR 44 (CR 55 R 66 )C(O)NR 77 or NR 44 (CR 55 R 66 )C(O)NR 77 ;
[0300] R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0301] Alternatively, the =N on L1 is linked to an atom on ring B to form a 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S or a 5-10 membered heteroaryl group containing 1-3 atoms selected from N, O or S, which is optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 In certain embodiments of the present invention, L1 is selected from NR 44 NR 44 C(O)NR 55 NR 44 S(O) n1 NR 55 NR 44 PR 66 (O) n1 NR 55 NR 44 C(=NR 77 )NR 55 、OC(O)NR 55 NR 44 C(O)O、NR 44 C(=S)NR 55 NR 44 C(O) n1 (CR 55 R 66 ), NR 44 (C 5-8 Cycloalkyl)(NR 55 ) n2 ,(NR 55 ) n2 NR 44 (5-8 membered heterocyclic group)(NR 55 ) n2 NR 44 (C 6-10 Aryl)(NR 55 ) n2 or NR 44 (5-8 membered heteroaryl)(NR 55 ) n2 ;
[0302] R 44 , R 55 , R66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0303] Alternatively, the =N on L1 is linked to an atom on ring B to form a 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S or a 5-10 membered heteroaryl group containing 1-3 atoms selected from N, O or S, which is optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The deuterated alkyl group is substituted with one or more substituents.
[0304] In certain embodiments of the present invention, L1 is selected from NR 44 C(O)NR 55 NR 44 S(O) n1 NR 55 NR 44 PR 66 (O) n1 NR 55 NR 44 C(=NR 77 )NR 55 、OC(O)NR 55 NR 44 C(O)O、NR 44 C(=S)NR 55 or NR 44 (5-8 membered heteroaryl)(NR 55 ) n2 ;
[0305] R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0306] Alternatively, the =N on L1 is linked to an atom on ring B to form a 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S or a 5-10 membered heteroaryl group containing 1-3 atoms selected from N, O or S, which is optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The deuterated alkyl group is substituted with one or more substituents.
[0307] In a further preferred embodiment of the present invention,
[0308] Ring A is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring A is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring A is selected from cyclopentyl, cyclohexyl, benzene ring, pyridine ring, pyrimidine ring, pyrazine, Optionally, it may be further substituted with one or more substituents selected from the group consisting of deuterium, oxo, thioxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl.
[0309] In a further preferred embodiment of the present invention,
[0310] Ring B is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring B is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring B is selected from benzene ring, pyridine ring, pyrimidine ring, thiazole,
[0311] Optionally, it may be further substituted with one or more substituents selected from the group consisting of deuterium, oxo, thioxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl.
[0312] In a further preferred embodiment of the present invention,
[0313] Ring C is selected from C 5-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, substituted by one or more substituents; Ring C is preferably Pyridine or pyrimidine, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 The aryl group or the 5-10 membered heteroaryl group containing 1-3 atoms selected from N, O or S atoms is substituted by one or more substituents.
[0314] In a further preferred embodiment of the present invention,
[0315] The ring fused to ring D and ring B1 is selected from C 6-10 Cycloalkyl, 6-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-12 aryl or 6-12 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S; preferably, the ring fused with ring D and ring B1 is selected from C 5-6 Cycloalkyl C 5-6 cycloalkyl, 5-6-membered heterocyclic radical containing 1-3 selected from N, O or S atoms and 5-6-membered heterocyclic radical containing 1-3 selected from N, O or S atoms, naphthyl, 5-6-membered heterocyclic radical containing 1-3 selected from N, O or S atoms and phenyl, 5-6-membered heterocyclic radical containing 1-3 selected from N, O or S atoms and 5-6-membered heteroaryl containing 1-3 selected from N, O or S atoms, phenyl and 5-6-membered heteroaryl containing 1-3 selected from N, O or S atoms, 5-6-membered heteroaryl containing 1-3 selected from N, O or S atoms and phenyl, or 5-6-membered heteroaryl containing 1-3 selected from N, O or S atoms and 5-6-membered heteroaryl containing 1-3 selected from N, O or S atoms and 5-6-membered heteroaryl containing 1-3 selected from N, O or S atoms, which may be further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, the ring fused with ring D and ring B1 is selected from
[0316] Optionally, it may be further substituted with one or more substituents selected from hydrogen, deuterium, oxo, thio, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl. In certain embodiments of the present invention, the ring D fused to the ring B1 is selected from
[0317] Optionally, it may be further substituted with one or more substituents selected from the group consisting of deuterium, oxo, thioxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl.
[0318] In a further preferred embodiment of the present invention, ring E is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; preferably, ring E is selected from Optionally, it may be further substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, oxo, thioxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl.
[0319] In certain embodiments of the present invention, ring E is selected from Optionally, it may be further substituted with one or more substituents selected from the group consisting of deuterium, oxo, thioxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl.
[0320] In a further preferred embodiment of the present invention, Ring A2 or Ring B2 are each independently selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring A2 or ring B2 are each independently selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring A2 or ring B2 are each independently selected from C 3-6 Cycloalkyl, 5-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; further preferably, ring A2 or ring B2 are each independently selected from benzene ring, pyridine, Optionally, it may be further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methanesulfonyl, cyclopropyl, cyclobutyl or azetidinyl;
[0321] Alternatively, ring C2 is present or absent, and when present is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring C2 is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring C2 is selected from C 3-6 Cycloalkyl, 5-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Preferably, the ring C2 is selected from cyclopropyl, cyclobutyl or azetidinyl, and may be further substituted by one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl.
[0322] In a further preferred embodiment of the present invention,
[0323] Ring B3 is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring B3 is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring B3 is selected from C 3-6 Cycloalkyl, 5-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S; further preferably, ring B3 is selected from benzene ring, pyridine, Optionally, it may be further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methanesulfonyl, cyclopropyl, cyclobutyl or azetidinyl;
[0324] Alternatively, ring C3 is present or absent, and when present is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring C3 is independently selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring C3 is selected from C 3-6 Cycloalkyl, 5-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; further preferably, ring C3 is selected from cyclopropyl, cyclobutyl or azetidinyl, optionally further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl;
[0325] Alternatively, Ring A3 is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring A3 is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring A3 is selected from C 3-6Cycloalkyl, 5-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Preferably, ring A3 is selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and may be further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl.
[0326] In certain embodiments of the present invention, Ring A is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring A is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring A is selected from a benzene ring, a pyridine ring or a pyrimidine ring, and optionally may be further substituted with one or more substituents selected from deuterium, oxo, thio, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl;
[0327] Ring B is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably ring B is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring B is selected from benzene ring, pyridine ring, pyrimidine ring, thiazole, Optionally, it may be further substituted with one or more substituents selected from deuterium, oxo, thioxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl;
[0328] Ring C is selected from C 5-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, substituted by one or more substituents; Ring C is preferably Pyridine or pyrimidine, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 substituted by one or more substituents of aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S;
[0329] The ring fused to ring D and ring B1 is selected from C 6-10 Cycloalkyl, 6-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-12aryl or 6-12 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, the ring fused with ring D and ring B1 is selected from Optionally, it may be further substituted with one or more substituents selected from deuterium, oxo, thioxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl;
[0330] Ring E is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; preferably, ring E is selected from Optionally, it may be further substituted with one or more substituents selected from the group consisting of deuterium, oxo, thioxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl.
[0331] In certain embodiments of the present invention,
[0332] Ring A is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring A is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, which may be further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring A is selected from a benzene ring, a pyridine ring or a pyrimidine ring, and optionally may be further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl;
[0333] Ring B is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably ring B is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring B is selected from a benzene ring, a pyridine ring or a pyrimidine ring, and optionally may be further substituted with one or more substituents selected from deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl;
[0334] Ring C is selected from C 5-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, which may be further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, substituted by one or more substituents; Ring C is preferably Pyridine or pyrimidine, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 substituted by one or more substituents of aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S;
[0335] Ring D is selected from 3-10 membered heterocyclic or 5-10 membered heteroaryl, optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The ring D preferably contains 1-3 3-8 membered heterocyclic groups selected from N, O or S atoms or 1-3 5-10 membered heteroaryl groups selected from N, O or S atoms, optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group; Ring D is more preferably Optionally substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The deuterated alkyl group is substituted with one or more substituents.
[0336] In a further preferred embodiment of the present invention,
[0337] R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 More preferably, R1 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, propyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl, oxirane, epoxypropyl or epoxybutyl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The deuterated alkyl group is substituted with one or more substituents.
[0338] In a further preferred embodiment of the present invention,
[0339] R2 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 1-3 Alkylthio, C 1-3 Halogenated alkylthio, halogenated thio, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R2 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 More preferably, R2 is each independently selected from hydrogen, deuterium, hydroxyl, halogen, cyano, amino, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl;
[0340] Alternatively, two R2 are linked to the adjacent carbon atom to form a C 3-10 Cycloalkyl or 3-10 membered heterocyclic group, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 The alkyl group is substituted with one or more substituents;
[0341] Preferably, two R2 are linked to the adjacent carbon atom to form a C 3-8 Cycloalkyl or 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 One or more substituents in the alkyl group are substituted;
[0342] More preferably, two R2 are linked to the adjacent carbon atom to form a C 3-6 Cycloalkyl or 3-6 membered heterocyclic group containing 1-3 N, O or S atoms, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 The alkyl group is substituted with one or more substituents;
[0343] Further preferably, two R2 are linked to the connected carbon atom to form a cyclopropyl, cyclobutyl or cyclopentyl group, which may optionally be further substituted by one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl.
[0344] In certain embodiments of the present invention,
[0345] R2 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R2 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 More preferably, R2 is each independently selected from hydrogen, deuterium, hydroxyl, halogen, cyano, amino, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl;
[0346] Alternatively, two R2 are linked to the adjacent carbon atom to form a C 3-10 Cycloalkyl or 3-10 membered heterocyclic group, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 The alkyl group is substituted with one or more substituents;
[0347] Preferably, two R2 are linked to the adjacent carbon atom to form a C 3-8 Cycloalkyl or 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 The alkyl group is substituted with one or more substituents;
[0348] More preferably, two R2 are linked to the adjacent carbon atom to form a C 3-6 Cycloalkyl or 3-6 membered heterocyclic group containing 1-3 N, O or S atoms, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 The alkyl group is substituted with one or more substituents;
[0349] Further preferably, two R2 are linked to the connected carbon atom to form a cyclopropyl, cyclobutyl or cyclopentyl group, which may optionally be further substituted by one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl.
[0350] In a further preferred embodiment of the present invention,
[0351] R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa Rbb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 ,, the C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl is substituted with one or more substituents;
[0352] Preferably, R3 is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl, 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 ,, the C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl, 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 substituted by one or more substituents of aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S;
[0353] More preferably, R3 is each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, propyl, vinyl, allyl, propenyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, propoxy, fluorine-substituted methoxy, fluorine-substituted ethoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl, cyano-substituted methyl, cyano-substituted ethyl, cyano-substituted propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, formyl, acetyl, -CH2C(O)NH2, -CH2S(O)2NH2, -NHC(O)CF3, -P(O)(CH3)2, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa Rbb ) n3 S(O) m1 R 32 ,, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 The alkyl group is substituted with one or more substituents;
[0354] R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-8 Cycloalkyl, 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10Aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group;
[0355] More preferably, R 31 or R 32 are each independently selected from deuterium, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, is substituted with one or more substituents.
[0356] In certain embodiments of the present invention,
[0357] R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -(CH2) n3 C(O)R 31 、-(CH2) n3 C(O)NR 31 R 32 、N=S=OR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 or -(CH2) n3 S(O) m1 R 32 , the C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl, 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, -(CH2) n3 C(O)R 31 、-(CH2) n3 C(O)NR 31 R 32 、N=S=OR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 or -(CH2) n3 S(O) m1 R 32 , the C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl, 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; More preferably, R3 is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, cyclopropyl, cyclobutyl, cyclohexyl, -(CH2) n3 C(O)R 31 、-(CH2) n3 C(O)NR 31 R 32 、N=S=OR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 or -(CH2) n3 S(O) m1 R 32 , which may be further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 The alkyl group is substituted with one or more substituents;
[0358] R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-8 Cycloalkyl, 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 More preferably, R 31 or R 32 are each independently selected from deuterium, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy or is substituted with one or more substituents.
[0359] In certain embodiments of the present invention,
[0360] R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -(CH2) n3 C(O)R 31 or -(CH2) n3 S(O) m1 R 32 , the C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl, 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, -(CH2) n3 C(O)R 31 or -(CH2) n3 S(O) m1 R 32 , the C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl, 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; More preferably, R3 is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, cyclopropyl, cyclobutyl, cyclohexyl, -(CH2) n3 C(O)R 31 or -(CH2) n3 S(O) m1 R 32 , which may be further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 The alkyl group is substituted with one or more substituents;
[0361] R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-8 Cycloalkyl, 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 More preferably, R 31 or R 32are each independently selected from deuterium, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl or is substituted with one or more substituents.
[0362] In a further preferred embodiment of the present invention,
[0363] R x1 or R x2 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R x1 or R x2 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 More preferably, R x1 or R x2Each is independently selected from hydrogen, deuterium, hydroxy, halogen, cyano, amino, methyl, ethyl, propyl or isopropyl.
[0364] In some embodiments, the compound prepared by the present invention shows an activity of about 1nM to 20nM (IC 50 ) biological activity; preferred compounds are less than about 1 nM, and more preferred compounds among the compounds listed in the present invention have an IC of less than 10 nM or even less than about 1 nM. 50 Value inhibitory activity.
[0365] IC values of the compounds prepared by the present invention for the proliferation inhibition activity of the test compounds on PI3Kα mutant cancer cells HCC1954 (H1047R), HGC-27 (E542K) and MKN1 (E545K) 50 IC less than 20nM 50 Value inhibitory activity.
[0366] The present invention further relates to a pharmaceutical composition comprising a therapeutically effective dose of any compound of the general formula shown, its stereoisomers or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.
[0367] In certain embodiments of the present invention, the weight percentage of the compound, its stereoisomer or pharmaceutically acceptable salt thereof in the pharmaceutical composition, calculated as the free base, is 0.1% to 95%, preferably 5-70%, for example 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10% or 5%.
[0368] In certain embodiments of the present invention, the pharmaceutical composition is selected from tablets, capsules, liquid preparations or injections, preferably, further comprising a filler, optionally a disintegrant, or further comprising one or more of a glidant or a lubricant.
[0369] In certain embodiments of the present invention, the pharmaceutical composition is an immediate-release formulation or a sustained-release formulation.
[0370] In certain embodiments of the present invention, the pharmaceutical composition, calculated as a free base, has a unit dose of 1-1000 mg, preferably 1-500 mg, or preferably 1 mg, 2 mg, 3 mg, 5 mg, 10 mg, 20 mg, 40 mg, 50 mg, 60 mg, 80 mg, 100 mg, 200 mg, 300 mg, 400 mg or 500 mg.
[0371] In certain embodiments of the invention, the compound, its stereoisomer or a pharmaceutically acceptable salt thereof, may be administered by any convenient method, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, intrathecal or transdermal administration, and the pharmaceutical composition adjusted accordingly.
[0372] In certain embodiments of the present invention, the compound, its stereoisomer or a pharmaceutically acceptable salt thereof can be formulated into liquid or solid preparations, such as syrups, suspensions, emulsions, tablets, capsules, powders, granules, or lozenges.
[0373] The present invention further relates to the use of any of the compounds of the general formula shown, its stereoisomers or pharmaceutically acceptable salts, or the pharmaceutical composition in the preparation of drugs for treating diseases related to PI3Kα.
[0374] The present invention further relates to the use of a compound of the general formula, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in the preparation of a drug for treating cancer, PROS (PIK3CA-related overgrowth spectrum), immune disorders or inflammatory disorders, preferably the PROS is selected from vascular malformations, lymphatic malformations and megalencephaly, and the cancer is selected from gastric cancer, breast cancer, prostate cancer, lung cancer, liver cancer, bone cancer, brain cancer, head and neck cancer, intestinal cancer, pancreatic cancer, bladder cancer, testicular cancer, ovarian cancer, endometrial cancer or multiple myeloma;
[0375] Clear cell ovarian cancer or breast cancer is preferred.
[0376] The present invention further relates to a method for using the compound represented by the general formula, its stereoisomers or pharmaceutically acceptable salts, or its pharmaceutical composition in the preparation of drugs for treating PI3Kα-related and related diseases.
[0377] The present invention also relates to a method for treating, preventing and / or treating diseases related to PI3Kα, which comprises administering to a patient a therapeutically effective dose of a compound represented by the general formula, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.
[0378] The present invention also provides methods of using the compounds or pharmaceutical compositions of the present invention to treat disease conditions, including but not limited to conditions associated with PI3Kα.
[0379] The present invention also relates to a method for treating a disease associated with PI3Kα in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof.
[0380] Detailed description of the invention
[0381] Unless stated otherwise, the terms used in the specification and claims have the following meanings.
[0382] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 8 carbon atoms, more preferably an alkyl group containing 1 to 6 carbon atoms, and most preferably an alkyl group containing 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof. More preferred are lower alkyl groups having 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available attachment point. The substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate groups. Methyl, ethyl, isopropyl, tert-butyl, haloalkyl, deuterated alkyl, alkoxy-substituted alkyl and hydroxy-substituted alkyl are preferred in the present invention.
[0383] The term "alkylene" refers to an alkyl group with one hydrogen atom further substituted, for example: "methylene" refers to -CH2-, "ethylene" refers to -(CH2)2-, "propylene" refers to -(CH2)3-, "butylene" refers to -(CH2)4-, etc. The term "alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, for example, vinyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc. The alkenyl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio.
[0384] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc.; polycyclic cycloalkyls include cycloalkyls of spiro rings, fused rings and bridged rings, preferably cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl and cycloheptyl.
[0385] The term "spirocycloalkyl" refers to a polycyclic group that shares a carbon atom (called a spiral atom) between 5 to 20 monocyclic rings, which may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of spiral atoms shared between rings, the spirocycloalkyl is divided into a single spiral cycloalkyl, a double spiral cycloalkyl or a multi-spirocycloalkyl, preferably a single spiral cycloalkyl and a double spiral cycloalkyl. More preferably, it is 3 yuan / 6 yuan, 3 yuan / 5 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spiral cycloalkyl. Non-limiting examples of spirocycloalkyl include:
[0386] .wait;
[0387] It also includes spirocycloalkyl groups that share a spiro atom with a heterocycloalkyl group. Non-limiting examples include:
[0388] wait.
[0389] The term "condensed cycloalkyl" refers to a 5 to 20-membered, all-carbon polycyclic group in which each ring in the system shares a pair of adjacent carbon atoms with other rings in the system, wherein one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic condensed cycloalkyl, preferably a bicyclic or tricyclic, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic alkyl. Non-limiting examples of condensed cycloalkyls include:
[0390] wait.
[0391] The term "bridged cycloalkyl" refers to a 5 to 20-membered, all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected, which may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 members, and more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, preferably a bicyclic, tricyclic or tetracyclic, and more preferably a bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyl include:
[0392]
[0393] The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring attached to the parent structure is a cycloalkyl, non-limiting examples of which include indanyl, tetrahydronaphthyl, benzocycloheptanyl, etc. The cycloalkyl may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.
[0394] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O). m (wherein m is an integer from 0 to 2) heteroatoms, but excluding the ring part of -OO-, -OS- or -SS-, the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, it contains 3 to 8 ring atoms; most preferably, it contains 3 to 8 ring atoms; further preferably, it contains 1-3 nitrogen atoms, 3-8 membered heterocyclic groups, optionally substituted by 1-2 oxygen atoms, sulfur atoms, oxo groups, including nitrogen-containing monocyclic heterocyclic groups, nitrogen-containing spiro heterocyclic groups or nitrogen-containing fused heterocyclic groups.
[0395] Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, azepanyl, 1,4-diazepanyl, pyranyl, etc., preferably pyrrolidinyl, morpholinyl, piperidinyl, azepanyl, 1,4-diazepanyl and piperazinyl. Polycyclic heterocyclic groups include spirocyclic, condensed and bridged heterocyclic groups; wherein the spirocyclic, condensed and bridged heterocyclic groups are optionally connected to other groups by single bonds, or further connected to other cycloalkyl, heterocyclic, aryl and heteroaryl groups by any two or more atoms on the ring.
[0396] The term "spiro heterocyclyl" refers to a polycyclic heterocyclic group in which the monocyclic rings of 5 to 20 members share one atom (called a spiro atom), wherein one or more of the ring atoms is selected from nitrogen, oxygen or S(O) m (wherein m is an integer 0 to 2) heteroatom, and the remaining ring atoms are carbon. It may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of shared spiral atoms between rings, spiral heterocyclic groups are divided into single spiral heterocyclic groups, double spiral heterocyclic groups or multi-spiro heterocyclic groups, preferably single spiral heterocyclic groups and double spiral heterocyclic groups. More preferably, it is 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spiral heterocyclic groups. Non-limiting examples of spiral heterocyclic groups include: wait.
[0397] The term "fused heterocyclyl" refers to a polycyclic heterocyclic group of 5 to 20 members, each ring in the system shares a pair of adjacent atoms with other rings in the system, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) m (wherein m is an integer from 0 to 2) heteroatoms, and the remaining ring atoms are carbon. Preferably 6 to 14 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, preferably a bicyclic or tricyclic, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic fused heterocyclic group. Non-limiting examples of fused heterocyclic groups include:
[0398]
[0399] wait.
[0400] The term "bridged heterocyclyl" refers to a 5- to 14-membered polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, which may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system, and one or more of the ring atoms is selected from nitrogen, oxygen or S(O) m (wherein m is an integer from 0 to 2) heteroatoms, and the remaining ring atoms are carbon. Preferably, it is 6 to 14 members, and more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, and more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclic groups include:
[0401]
[0402] wait.
[0403] The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring attached to the parent structure is a heterocyclyl, non-limiting examples of which include:
[0404] wait.
[0405] The heterocyclyl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.
[0406] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., a ring sharing adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably 6- to 12-membered, such as phenyl and naphthyl. More preferably phenyl. The aryl ring may be fused to a heteroaryl, heterocyclic or cycloalkyl ring, including benzo 5-10-membered heteroaryl, benzo 3-8-membered cycloalkyl and benzo 3-8-membered heteroalkyl, preferably benzo 5-6-membered heteroaryl, benzo 3-6-membered cycloalkyl and benzo 3-6-membered heteroalkyl, wherein the heterocyclic group is a heterocyclic group containing 1-3 nitrogen atoms, oxygen atoms, and sulfur atoms; or further comprising a three-membered nitrogen-containing fused ring containing a benzene ring.
[0407] Wherein the ring attached to the parent structure is an aryl ring, non-limiting examples of which include:
[0408]
[0409] wait.
[0410] The aryl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0411] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms and 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. The heteroaryl is preferably 5 to 12-membered, more preferably 5-membered or 6-membered, such as imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, thiadiazole, pyrazinyl, etc., preferably triazolyl, thienyl, imidazolyl, pyrazolyl, oxazolyl, pyrimidyl or thiazolyl; more preferably pyrazolyl, pyrrolyl and oxazolyl. The heteroaryl ring can be fused to an aryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, and non-limiting examples thereof include:
[0412]
[0413] wait.
[0414] The heteroaryl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0415] The term "alkoxy" refers to-O-(alkyl) and-O-(unsubstituted cycloalkyl), wherein the definition of alkyl is as described above. The non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy. Alkoxy can be optionally substituted or unsubstituted, and when substituted, substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, sulfhydryl, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0416] "Haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
[0417] "Haloalkoxy" refers to an alkoxy group substituted with one or more halogens, wherein alkoxy is as defined above.
[0418] "Hydroxyalkyl" refers to an alkyl group substituted with a hydroxy group, wherein alkyl is as defined above.
[0419] "Alkenyl" refers to a chain alkenyl group, also known as an alkene group, wherein the alkenyl group can be further substituted by other related groups, for example: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0420] "Alkynyl" refers to (CH≡C-), wherein the alkynyl can be further substituted by other related groups, for example: alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, thiol, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0421] The term "alkenylcarbonyl" refers to -C(O)-(alkenyl), wherein the definition of alkenyl is as described above. Non-limiting examples of alkenylcarbonyl include: vinylcarbonyl, propenylcarbonyl, butenylcarbonyl. Alkenylcarbonyl can be optionally substituted or unsubstituted, and when substituted, substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, sulfhydryl, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.
[0422] "Hydroxy" refers to an -OH group.
[0423] "Halogen" refers to fluorine, chlorine, bromine or iodine.
[0424] "Amino" refers to -NH2.
[0425] "Cyano" refers to -CN.
[0426] "Nitro" refers to -NO2.
[0427] "Carbonyl" refers to -C(O)-.
[0428] "Carboxy" refers to -C(O)OH.
[0429] "THF" refers to tetrahydrofuran.
[0430] "EtOAc" means ethyl acetate.
[0431] "MeOH" refers to methanol.
[0432] "DMF" refers to N,N-dimethylformamide.
[0433] "DIPEA" refers to diisopropylethylamine.
[0434] "TFA" refers to trifluoroacetic acid.
[0435] "MeCN" refers to acetylene.
[0436] "DMA" refers to N,N-dimethylacetamide.
[0437] "Et2O" refers to diethyl ether.
[0438] "DCE" refers to 1,2-dichloroethane.
[0439] "DIPEA" refers to N,N-diisopropylethylamine.
[0440] "NBS" refers to N-bromosuccinimide.
[0441] "NIS" refers to N-iodosuccinimide.
[0442] Different expressions such as “X is selected from A, B, or C”, “X is selected from A, B and C”, “X is A, B or C”, “X is A, B and C” all express the same meaning, that is, X can be any one or more of A, B, C.
[0443] The hydrogen atoms described in the present invention can be replaced by their isotope deuterium, and any hydrogen atom in the example compounds of the present invention can also be replaced by a deuterium atom.
[0444] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.
[0445] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group are replaced independently of each other by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the skilled person can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (e.g. olefinic) bonds.
[0446] "Pharmaceutical composition" means a mixture containing one or more compounds described herein or their physiologically / pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.
[0447] "Pharmaceutically acceptable salt" and "pharmaceutically usable salt" refer to salts of the compounds of the present invention, which are safe and effective when used in mammals and have the desired biological activity. DETAILED DESCRIPTION
[0448] Example
[0449] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10 -6 The unit of (ppm) is given. NMR measurements were performed using a Bruker AVANCE-400 NMR spectrometer, with deuterated dimethyl sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD) as the solvent, and tetramethylsilane (TMS) as the internal standard.
[0450] MS was measured using a FINNIGAN LCQAd (ESI) mass spectrometer (manufacturer: Thermo, model: Finnigan LCQadvantage MAX).
[0451] HPLC analysis was performed using an Agilent 1200DAD high pressure liquid chromatograph (Sunfire C18 150×4.6 mm column) and a Waters 2695-2996 high pressure liquid chromatograph (Gimini C18 150×4.6 mm column).
[0452] Average kinase inhibition rate and IC 50 The values were determined using NovoStar microplate reader (BMG, Germany).
[0453] The thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate. The silica gel plate used in thin layer chromatography (TLC) adopts a specification of 0.15mm-0.2mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm-0.5mm.
[0454] Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.
[0455] The known starting materials of the present invention can be synthesized by methods known in the art, or can be purchased from ABCR GmbH & Co. KG, Acros Organics, Aldrich Chemical Company, AccelaChemBio Inc, Darui Chemicals and other companies.
[0456] Unless otherwise specified in the examples, the reactions can be carried out under an argon atmosphere or a nitrogen atmosphere.
[0457] Argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a capacity of about 1L.
[0458] Hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1L.
[0459] The pressurized hydrogenation reaction uses a Parr 3916EKX hydrogenator and a Qinglan QL-500 hydrogen generator or a HC2-SS hydrogenator.
[0460] The hydrogenation reaction is usually carried out by evacuating the vacuum, filling with hydrogen, and repeating the operation three times.
[0461] The microwave reaction was carried out using a CEM Discover-S 908860 microwave reactor.
[0462] Unless otherwise specified in the examples, the solution refers to an aqueous solution.
[0463] Unless otherwise specified in the examples, the reaction temperature is room temperature, 20°C to 30°C.
[0464] The reaction progress in the embodiment is monitored by thin layer chromatography (TLC), and the developing solvent system used in the reaction is: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: petroleum ether and ethyl acetate system, D: acetone, and the volume ratio of the solvent is adjusted according to the polarity of the compound. The eluent system of column chromatography and the developing solvent system of thin layer chromatography used for purifying the compound include: A: dichloromethane and methanol system, B: n-hexane and ethyl acetate system, C: dichloromethane and acetone system, and the volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine and acetic acid can also be added for adjustment.
[0465] Example 1
[0466] 1-[(2-aminopyrimidin-5-yl)amino]-N-[1-(3-cyclopropyl-5-fluoro-1-benzofuran-2-yl)-2-methylpropyl]methaneamide
[0467]
[0468] first step
[0469] 1-(3-Cyclopropyl-5-fluoro-1-benzofuran-2-yl)-2-methylpropan-1-one
[0470] Cyclopropyl (5-fluoro-2-hydroxyphenyl) ketone (200 mg, 1.11 mmol) was dissolved in N, N-dimethylacetamide (10 mL), and potassium carbonate (307 mg, 2.22 mmol) and 1-bromo-3-methylbutan-2-one (202 mg, 1.22 mmol) were added in sequence. The reaction solution was heated at 120 ° C for 4 hours in a microwave. After cooling to room temperature, 20 mL of water was added to the reaction solution, and it was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system C to obtain the title product 1a (175 mg, yield: 71.6%).
[0471] MS m / z(ESI):221.1[M+1]
[0472] Step 2
[0473] 1-(3-Cyclopropyl-5-fluoro-1-benzofuran-2-yl)-2-methylpropan-1-amine
[0474] A solution of 1-(3-cyclopropyl-5-fluoro-1-benzofuran-2-yl)-2-methylpropan-1-one (175 mg, 0.80 mmol), sodium sulfate (100 mg, 0.7 mmol) and ammonium acetate (616 mg, 8.00 mmol) in methanol (4 mL) was stirred at room temperature for 1 hour, and then sodium cyanoborohydride (47 mg, 0.75 mmol) was added and reacted at 80°C for 24 hours. After the reaction was completed, the reaction solution was filtered, the filter cake was washed with 5 mL of methanol, the filtrate was concentrated under reduced pressure, the crude product obtained was dissolved in 10% sodium hydroxide aqueous solution (20 mL), and then extracted with dichloromethane (20 mL×3), the organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system A to obtain the title product 1b (120 mg, yield: 60.7%). MS m / z(ESI):248.1[M+1]
[0475] Step 3
[0476] 1-[(2-aminopyrimidin-5-yl)amino]-N-[1-(3-cyclopropyl-5-fluoro-1-benzofuran-2-yl)-2-methylpropyl]methaneamide
[0477] At 0°C, triphosgene (65 mg, 0.22 mmol) was added to a solution of 1-(3-cyclopropyl-5-fluoro-1-benzofuran-2-yl)-2-methylpropan-1-amine (120 mg, 0.49 mmol) and triethylamine (147 mg, 1.47 mmol) in dichloromethane (3 mL). The reaction solution was stirred at room temperature for 1 hour, and pyrimidine-2,5-diamine (54 mg, 0.49 mmol) was added under ice bath, and continued to stir at room temperature for 1 hour. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and the obtained residue was purified by preparative HPLC to obtain the title product 1 (26 mg, yield: 13.8%). MS m / z (ESI): 384.2 [M+1].
[0478] Embodiment 55
[0479] 6-[Dimethyl(oxyylidene)-λ5-methylphosphinoyl]-2-{[1-(5-fluoro-3-methyl-1-benzofuran-2-yl)-2-methylpropyl]amino}-1H-benzo[d]imidazole
[0480]
[0481] first step
[0482] 1-(3-Methyl-5-fluoro-1-benzofuran-2-yl)-2-methylpropan-1-one
[0483] Methyl (5-fluoro-2-hydroxyphenyl) ketone (200 mg, 1.11 mmol) was dissolved in 10 mL N, N-dimethylacetamide, and potassium carbonate (307 mg, 2.22 mmol) and 1-bromo-3-methylbutan-2-one (202 mg, 1.22 mmol) were added in sequence. The reaction solution was heated at 120 ° C for 4 hours in a microwave oven. After cooling to room temperature, 20 mL of water was added to the reaction solution, and it was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system C to obtain the title product 1-(3-methyl-5-fluoro-1-benzofuran-2-yl)-2-methylpropan-1-one 175 mg, yield: 71.6%. MS m / z (ESI): 221.1 [M+1]
[0484] Step 2
[0485] 1-(3-methyl-5-fluoro-1-benzofuran-2-yl)-2-methylpropan-1-amine
[0486] A solution of 1-(3-methyl-5-fluoro-1-benzofuran-2-yl)-2-methylpropan-1-one (175 mg, 0.80 mmol), sodium sulfate (100 mg, 0.7 mmol) and ammonium acetate (616 mg, 8.00 mmol) in methanol (4 mL) was stirred at room temperature for 1 hour, and then sodium cyanoborohydride (47 mg, 0.75 mmol) was added and reacted at 80°C for 24 hours. After the reaction was completed, the reaction solution was filtered, the filter cake was washed with 5 mL of methanol, and the filter cake was filtered. The crude product obtained by vacuum concentration was dissolved in 10% sodium hydroxide aqueous solution (20 mL), extracted with dichloromethane (20 mL×3), the organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography with eluent system A to obtain 120 mg of the title product 1-(3-methyl-5-fluoro-1-benzofuran-2-yl)-2-methylpropan-1-amine, with a yield of 68.1%. MS m / z (ESI): 222.1 [M+1]
[0487] Step 3
[0488] (4-Fluoro-3-nitrophenyl)dimethyl(oxyylidene)-λ5-methylphosphine
[0489] 1-Fluoro-4-iodo-2-nitrobenzene (200 mg, 0.75 mmol) was dissolved in 4 mL of dioxane, and dimethyl (oxyylidene)-λ5-methylphosphine (92 mg, 1.5 mmol) and cesium carbonate (489 mg, 1.5 mmol) were added to the reaction solution in sequence. After the reaction solution was replaced with nitrogen three times, tris (dibenzylideneacetone) dipalladium (69 mg, 0.075 mmol) and 4,5-bis (diphenylphosphine)-9,9-dimethylxanthene (87 mg, 0.15 mmol) were added. The reaction was carried out at 90°C for 3 hours. After the reaction was completed, the reaction solution was filtered, the filter cake was washed with 5 mL of methanol, and the filtrate was concentrated under reduced pressure to obtain a crude product. The residue was purified by silica gel column chromatography with eluent system A to obtain 127 mg of the title product (4-fluoro-3-nitrophenyl) dimethyl (oxyylidene)-λ5-methylphosphine, with a yield of 78%.
[0490] MS m / z(ESI):218.0[M+1]
[0491] Step 4
[0492] 4-[Dimethyl(oxyylidene)-λ5-methylphosphino]-2-nitroaniline
[0493] Dissolve (4-fluoro-3-nitrophenyl)dimethyl(oxyylidene)-λ5-methylphosphine (500 mg, 2.3 mmol) in 5 mL of methanol, add ammonia water (11.4 mL, 4M, 45.6 mmol), and react the reaction solution at 100°C for 3 hours under microwave conditions. After the reaction is completed, the reaction solution is concentrated under reduced pressure to obtain a crude product, which is purified by silica gel column chromatography using eluent system A to obtain the title product 4-[dimethyl(oxyylidene)-λ5-methylphosphino]-2-nitroaniline 420 mg, yield: 85.2%. MS m / z (ESI): 215.1 [M+1]
[0494] Step 5
[0495] 4-[Dimethyl(oxyylidene)-λ5-methylphosphino]benzene-1,2-diamine
[0496] 4-[Dimethyl(oxyylidene)-λ5-methylphosphino]-2-nitroaniline (100 mg, 0.46 mmol) was dissolved in 3 mL of ethanol, and a solution of ammonium chloride (71 mg, 1.4 mmol) in water (1 mL) was added, and then iron powder (129 mg, 2.31 mmol) was added. The reaction solution was reacted at 80°C for 2 hours. After the reaction was completed, the reaction solution was filtered through diatomaceous earth, the filter cake was rinsed with 3 mL of ethanol, and the filtrate was concentrated under reduced pressure to obtain a crude product. The residue was purified by silica gel column chromatography with eluent system A to obtain the title product 4-[dimethyl(oxyylidene)-λ5-methylphosphino]benzene-1,2-diamine 70 mg, yield: 81.4%. MS m / z (ESI): 185.1 [M+1]
[0497] Step 6
[0498] 6-[dimethyl(oxyylidene)-λ5-methylphosphinoyl]-2-{[1-(5-fluoro-3-methyl-1-benzofuran-2-yl)-2-methylpropyl]
[0499] Amino}-1H-benzo[d]imidazole
[0500] At 0°C, triphosgene (65 mg, 0.22 mmol) was added to a solution of 1-(3-methyl-5-fluoro-1-benzofuran-2-yl)-2-methylpropan-1-amine (120 mg, 0.49 mmol) and triethylamine (147 mg, 1.47 mmol) in acetonitrile (3 mL). After the reaction solution was stirred for 1 hour, 4-[dimethyl(oxyylidene)-λ5-methylphosphino]benzene-1,2-diamine (90 mg, 0.49 mmol) was added under ice bath, and the mixture was stirred at room temperature for 1 hour. Then, ethyl[di(propan-2-yl)]amine (310 mg, 2.4 mmol) and iodobenzene acetate (238 mg, 0.74 mmol) were added in sequence, and the mixture was stirred at room temperature for 3 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure, and the residue was purified by preparative HPLC to obtain the title product 55 (41.3 mg, yield: 20.4%). MS m / z(ESI):414.2[M+1].
[0501] Embodiment 107
[0502] N-(1-(5-Fluoro-3-methylbenzofuran-2-yl)-2-methylpropyl)-6-(methylsulfonyl)thiazo[5,4-b]pyridin-2-amine
[0503]
[0504] first step
[0505] tert-Butyl (6-bromothiazolo[5,4-b]pyridin-2-yl)carbamate
[0506] 6-Bromothiazolo[5,4-b]pyridin-2-amine (500 mg, 2.17 mmol), Boc2O (712 mg, 3.26 mmol), and triethylamine (660 mg, 6.52 mmol) were dissolved in THF (10 mL) and stirred at room temperature for 2 hours. Saturated ammonium chloride solution was added to the reaction solution to quench the reaction, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 509 mg of the title product (6-bromothiazolo[5,4-b]pyridin-2-yl)carbamic acid tert-butyl ester, with a yield of 70.9%. MS m / z (ESI): 330.2 [M+1]
[0507] Step 2
[0508] tert-Butyl (6-(methylsulfonyl)thiazolo[5,4-b]pyridin-2-yl)carbamate
[0509] 107a (509 mg, 1.54 mmol), sodium methanesulfinate (189 mg, 1.85 mmol), cuprous iodide (29 mg, 0.15 mmol), and L-proline (35 mg, 0.31 mmol) were dispersed in DMSO (10 mL), and the reaction solution was heated to 90 ° C and stirred for 24 hours. Saturated ammonium chloride solution was added to the reaction solution to quench the reaction, and extracted with ethyl acetate (20 mL × 3), the organic phases were combined, washed once with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 419 mg of the title product (6-(methylsulfonyl)thiazolo[5,4-b]pyridin-2-yl)carbamic acid tert-butyl ester, yield: 82.5%. MS m / z (ESI): 330.1 [M+1]
[0510] Step 3
[0511] 6-(Methylsulfonyl)thiazo[5,4-b]pyridin-2-amine
[0512] 107b (419 mg, 1.27 mmol) was dissolved in 10 mL of trifluoroacetic acid and stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to obtain 225 mg of the title product 6-(methylsulfonyl)thiazo[5,4-b]pyridin-2-amine, with a yield of 77.2%. MS m / z (ESI): 230.0 [M+1]
[0513] Step 4
[0514] N-(1-(5-Fluoro-3-methylbenzofuran-2-yl)-2-methylpropyl)-6-(methylsulfonyl)thiazo[5,4-b]pyridin-2-amine
[0515] 6-(Methylsulfonyl)thiazolyl[5,4-b]pyridin-2-amine (225 mg, 0.98 mmol), 1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylpropan-1-one (216 mg, 0.98 mmol), and tetraisopropoxytitanium (279 mg, 0.98 mmol) were dissolved in 5 mL of dichloromethane and stirred at room temperature for 18 hours. Sodium borohydride (73 mg, 1.96 mmol) was then added to the reaction solution, and the reaction was stirred at room temperature for another hour. Saturated ammonium chloride solution was added to the reaction solution to quench the reaction, and the mixture was extracted with dichloromethane (10 mL×3). The organic phases were combined, washed once with saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 295 mg of the title product 107, with a yield of 69.3%.
[0516] MS m / z(ESI):434.1[M+1]
[0517] Embodiment 114
[0518] 1-(2-(3,3-difluoroazetidin-1-yl)pyrimidin-5-yl)-3-(8-fluoro-1,2,3,4-tetrahydrodibenzo[b,d]furan-4-yl)urea
[0519]
[0520] first step
[0521] 1-(5-Fluorobenzofuran-3-yl)cyclobutan-1-ol
[0522] 3-Bromo-5-fluorobenzofuran (500 mg, 2.33 mmol) was dissolved in THF (20 mL). Under dry ice ethanol bath cooling, n-butyl lithium (1.0 mL, 2.5 M in hexane) was added to the reaction solution and stirred for 1 hour. Cyclobutanone (163 mg, 2.33 mmol) was then added to the reaction solution and stirred for 2 hours. Saturated ammonium chloride solution was added to the reaction solution to quench the reaction, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 312 mg of the title product 1-(5-fluorobenzofuran-3-yl)cyclobutane-1-ol, with a yield of 65.1%. MS m / z (ESI): 207.1 [M+1]
[0523] Step 2
[0524] 8-Fluoro-2,3-dihydrodibenzo[b,d]furan-4(1H)-one
[0525] 3-Bromo-5-fluorobenzofuran (500 mg, 2.33 mmol) was dissolved in THF (20 mL). Under dry ice ethanol bath cooling, n-butyl lithium (1.0 mL, 2.5 M in hexane) was added to the reaction solution and stirred for 1 hour. Cyclobutanone (163 mg, 2.33 mmol) was then added to the reaction solution and stirred for 2 hours. Saturated ammonium chloride solution was added to the reaction solution to quench the reaction, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 312 mg of the title product 8-fluoro-2,3-dihydrodibenzo[b, d]furan-4(1H)-one, with a yield of 65.1%. MS m / z (ESI): 205.1 [M+1]
[0526] Step 3
[0527] 8-Fluoro-1,2,3,4-tetrahydrodibenzo[b,d]furan-4-amine
[0528] 8-Fluoro-2,3-dihydrodibenzo[b,d]furan-4(1H)-one (312mg, 1.53mmol) was dissolved in NH3 (7Min MeOH, 10mL), tetraisopropoxytitanium (435mg, 1.53mmol) was added to the reaction solution, and the reaction was stirred at room temperature for 16 hours. Sodium borohydride (170mg, 4.59mmol) was then added to the reaction solution, and the reaction was continued to stir for 1 hour. Saturated ammonium chloride solution was added to the reaction solution to quench the reaction, and the mixture was extracted with ethyl acetate (20mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 246mg of the title product 8-fluoro-1,2,3,4-tetrahydrodibenzo[b,d]furan-4-amine, with a yield of 78.5%. MS m / z(ESI):206.1[M+1]
[0529] Step 4
[0530] 1-(2-(3,3-difluoroazetidin-1-yl)pyrimidin-5-yl)-3-(8-fluoro-1,2,3,4-tetrahydrodibenzo[b,d]furan-4-yl)urea
[0531] Example 114 was prepared by referring to the synthesis method of Example 1. MS m / z (ESI): 418.1 [M+1]
[0532] Embodiment 117
[0533] N-(2-(azetidin-1-yl)pyrimidin-5-yl)-1,1,1-trifluoro-N'-((R)-2,2,2-trifluoro-1-(5-fluoro-3-methylbenzofuran-2-yl)ethyl)propane-2,2-diamine
[0534]
[0535] first step
[0536] (E)-1,1,1-Trifluoro-N-(2,2,2-trifluoro-1-(5-fluoro-3-methylbenzofuran-2-yl)ethyl)propane-2-imine
[0537] Dissolve 2,2,2-trifluoro-1-(5-fluoro-3-methylbenzofuran-2-yl)ethane-1-amine (500 mg, 2.02 mmol) and 1,1,1-trifluoroacetone (272 mg, 2.43 mmol) in dichloromethane (20 mL). Stir and react at room temperature for 3 hours. Concentrate the reaction solution under reduced pressure to obtain 611 mg of the title product 1-(5-fluorobenzofuran-3-yl)cyclobutane-1-ol, with a yield of 88.5%. MS m / z (ESI): 342.1 [M+1]
[0538] Step 2
[0539] N-(2-(azetidin-1-yl)pyrimidin-5-yl)-1,1,1-trifluoro-N'-((R)-2,2,2-trifluoro-1-(5-fluoro-3-methylbenzofuran-2-yl)ethyl)propane-2,2-diamine
[0540] 1-(5-Fluorobenzofuran-3-yl)cyclobutane-1-ol (611 mg, 1.79 mmol) and 2-(azetidin-1-yl)pyrimidin-5-amine (296 mg, 1.97 mmol) were dissolved in THF (20 mL) and stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 454 mg of the title product N-(2-(azetidin-1-yl)pyrimidin-5-yl)-1,1,1-trifluoro-N'-((R)-2,2,2-trifluoro-1-(5-fluoro-3-methylbenzofuran-2-yl)ethyl)propane-2,2-diamine, with a yield of 51.6%.
[0541] MS m / z(ESI):492.2[M+1]
[0542] Embodiment 118
[0543] 2-((2,2,2-trifluoro-1-(5-fluoro-3-methylbenzofuran-2-yl)ethyl)amino)-1H-imidazole-4-carbonitrile
[0544]
[0545] 2,2,2-Trifluoro-1-(5-fluoro-3-methylbenzofuran-2-yl)ethane-1-amine (500 mg, 2.02 mmol), 2-bromo-1H-imidazole-4-carbonitrile (348 mg, 2.02 mmol), BrettPhos-Pd-G4 (19 mg, 0.20 mmol), cesium carbonate (2.0 g, 6.06 mmol) were dispersed in DMF (10 mL), and the reaction solution was heated to 110° C. and stirred for 16 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 118505 mg of the title product, with a yield of 73.8%.
[0546] MS m / z(ESI):339.1[M+1]
[0547] Embodiment 119
[0548] 2-(3,3-Difluoroazetidin-1-yl)-9-(1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylpropyl)-7,9-dihydro-8H-purin-8-one
[0549]
[0550] first step
[0551] 1-(5-Fluoro-3-methylbenzofuran-2-yl)-2-methylpropan-1-ol
[0552] 1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylpropan-1-one (300 mg, 1.36 mmol) was dissolved in methanol (20 mL), sodium borohydride (151 mg, 4.08 mmol) was added to the reaction solution, and the reaction was stirred at room temperature for 1 hour. Saturated ammonium chloride solution was added to the reaction solution to quench the reaction, and ethyl acetate was used for extraction (20 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title product 1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylpropan-1-ol 288 mg, yield: 95.1%. MS m / z(ESI):223.1[M+1]
[0553] Step 2
[0554] 1-(5-Fluoro-3-methylbenzofuran-2-yl)-2-methylmethanesulfonic acid propyl ester
[0555] 1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylpropan-1-ol (288 mg, 1.30 mmol), triethylamine (394 mg, 3.89 mmol), MsCl (223 mg, 1.94 mmol) were dissolved in dichloromethane (20 mL) and stirred at room temperature for 1 hour. Saturated ammonium chloride solution was added to the reaction solution to quench the reaction, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title product 1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylmethanesulfonic acid propyl ester 352 mg, yield: 90.5%. MS m / z (ESI): 301.1 [M+1]
[0556] Step 3
[0557] 2-(3,3-Difluoroazetidin-1-yl)-9-(1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylpropyl)-7,9-dihydro-8H-purin-8-one
[0558] 2-(3,3-difluoroazetidine-1-yl)-7,9-dihydro-8H-purine-8-one (50 mg, 0.22 mmol) and NaH (26.4 mg, 0.66 mmol, 60% wt.) were dispersed in tetrahydrofuran (5 mL) and stirred at room temperature for 1 hour. Then 1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylmethanesulfonic acid propyl ester (66 mg, 0.22 mmol) was added to the reaction solution, and the reaction solution was heated to 50°C and stirred for 15 hours. Saturated ammonium chloride solution was added to the reaction solution to quench the reaction, and the mixture was extracted with ethyl acetate (10 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 42 mg of the title product 2-(3,3-difluoroazetidine-1-yl)-9-(1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylpropyl)-7,9-dihydro-8H-purine-8-one, with a yield of 44.2%. MS m / z(ESI):431.4[M+1]
[0559] Embodiment 124
[0560] 3-(2-(3,3-difluoroazetidin-1-yl)pyrimidin-5-yl)-N-(1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylpropyl)pyridin-2-amine
[0561]
[0562] first step
[0563] 5-(2-chloropyridin-3-yl)-2-(3,3-difluoroazetidin-1-yl)pyrimidine
[0564] Disperse (2-chloropyridin-3-yl)boric acid (500 mg, 3.18 mmol), 5-bromo-2-(3,3-difluoroazetidine-1-yl)pyrimidine (795 mg, 3.18 mmol), Pd(dppf)Cl2 (233 mg, 0.32 mmol), and potassium carbonate (1.3 g, 9.54 mmol) in 1,4-dioxnae (20 mL), replace with nitrogen protection, and heat the reaction solution to 100 ° C and stir for 18 hours. The reaction solution was cooled to room temperature, filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title product 5-(2-chloropyridin-3-yl)-2-(3,3-difluoroazetidine-1-yl)pyrimidine 796 mg, with a yield of 88.6%. MS m / z (ESI): 283.1 [M+1]
[0565] Step 2
[0566] 3-(2-(3,3-difluoroazetidin-1-yl)pyrimidin-5-yl)-N-(1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylpropyl)pyridin-2-amine
[0567] 5-(2-chloropyridin-3-yl)-2-(3,3-difluoroazetidine-1-yl)pyrimidine (100 mg, 0.35 mmol), 1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylpropan-1-amine (78 mg, 0.35 mmol), and DIEA (92 mg, 0.71 mmol) were dissolved in DMSO (5 mL), and the reaction solution was heated to 80°C and stirred for 3 hours. The reaction solution was cooled to room temperature and purified by preparative HPLC to obtain the title product 3-(2-(3,3-difluoroazetidine-1-yl)pyrimidin-5-yl)-N-(1-(5-fluoro-3-methylbenzofuran-2-yl)-2-methylpropyl)pyridin-2-amine 121 mg, yield: 73.2%. MS m / z(ESI):468.2[M+1]
[0568] Embodiment 128
[0569] N-(2-(3,3-difluoroazetidin-1-yl)pyrimidin-5-yl)-4-(5-fluoro-3-methylbenzofuran-2-yl)thiazol-2-amine
[0570]
[0571] first step
[0572] N-(4-(3,3-Difluoroazetidin-1-yl)phenyl)thiazol-2-amine
[0573] Disperse 2-bromothiazole (300 mg, 1.83 mmol), 4-(3,3-difluoroazetidin-1-yl)aniline (337 mg, 1.83 mmol), BrettPhos-Pd-G4 (169 mg, 0.18 mmol), and cesium carbonate (1.8 g, 5.49 mmol) in DMF (10 mL), and heat the reaction solution to 110°C and stir for 16 hours. Concentrate the reaction solution under reduced pressure, and purify the residue by silica gel column chromatography to obtain 346 mg of the title product N-(4-(3,3-difluoroazetidin-1-yl)phenyl)thiazole-2-amine, with a yield of 70.8%. MS m / z (ESI): 268.1 [M+1]
[0574] Step 2
[0575] 4-Bromo-N-(4-(3,3-difluoroazetidin-1-yl)phenyl)thiazol-2-amine
[0576] N-(4-(3,3-difluoroazetidin-1-yl)phenyl)thiazol-2-amine (346 mg, 1.29 mmol) and NBS (254 mg, 1.42 mmol) were dissolved in DMF (15 mL) and stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography to obtain the title product 4-bromo-N-(4-(3,3-difluoroazetidin-1-yl)phenyl)thiazol-2-amine 358 mg, yield: 79.9%. MS m / z (ESI): 346.0 [M+1]
[0577] Step 3
[0578] (5-Fluoro-3-methylbenzofuran-2-yl)boronic acid
[0579] 5-Fluoro-3-methylbenzofuran (500 mg, 3.33 mmol) was dissolved in THF (20 mL). Under dry ice ethanol bath cooling, n-butyl lithium (1.5 mL, 2.5 M in hexane) was added to the reaction solution and stirred for 1 hour. Trimethyl borate (1.0 g, 9.99 mmol) was then added to the reaction solution and stirred for 2 hours. Saturated ammonium chloride solution was added to the reaction solution to quench the reaction, and the mixture was extracted with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 516 mg of the title product (5-fluoro-3-methylbenzofuran-2-yl) boronic acid, with a yield of 79.9%. MS m / z (ESI): 195.1 [M+1]
[0580] Step 4
[0581] N-(2-(3,3-difluoroazetidin-1-yl)pyrimidin-5-yl)-4-(5-fluoro-3-methylbenzofuran-2-yl)thiazol-2-amine
[0582] 4-Bromo-N-(4-(3,3-difluoroazetidin-1-yl)phenyl)thiazol-2-amine (100 mg, 0.29 mmol), (5-fluoro-3-methylbenzofuran-2-yl)boric acid (56 mg, 0.29 mmol), Pd(dppf)Cl2 (23 mg, 0.03 mmol), potassium carbonate (120 mg, 0.87 mmol) were dispersed in 1,4-dioxnae (5 mL), replaced with nitrogen protection, and the reaction solution was heated to 100°C and stirred for 18 hours. The reaction solution was cooled to room temperature, filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title product N-(2-(3,3-difluoroazetidin-1-yl)pyrimidin-5-yl)-4-(5-fluoro-3-methylbenzofuran-2-yl)thiazol-2-amine 82 mg, with a yield of 68.0%. MS m / z(ESI):418.1[M+1]
[0583] Embodiment 141
[0584] (R)-5-(2-((1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)amino)-1H-imidazol-5-yl)pyrimidin-2-amine
[0585]
[0586] first step
[0587] (R)-5-Bromo-N-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)-1H-imidazol-2-amine
[0588] 1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethane-1-one (300 mg, 1.14 mmol), 5-bromo-1H-imidazole-2-amine (203 mg, 1.25 mmol), trimethylsilyl chloride (372 mg, 3.42 mmol) were dissolved in DMF (10 mL) and stirred at room temperature for 16 hours. Subsequently, sodium cyanoborohydride (255 mg, 6.84 mmol) was added to the reaction solution and stirred for 2 hours. Saturated ammonium chloride solution was added to the reaction solution to quench the reaction, and the mixture was extracted with ethyl acetate (20 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 366 mg of the title product (R)-5-bromo-N-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)-1H-imidazole-2-amine, with a yield of 78.6%. MS m / z(ESI):410.0[M+1]
[0589] Step 2
[0590] (R)-5-(2-((1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)amino)-1H-imidazol-5-yl)pyrimidin-2-amine
[0591] 141a (366 mg, 0.892 mmol), (2-aminopyrimidin-5-yl)boric acid (149 mg, 1.07 mmol), Pd(dppf)Cl2 (65 mg, 0.089 mmol), potassium carbonate (370 mg, 2.68 mmol) were dispersed in DMF (10 mL), and the reaction solution was heated to 100°C and stirred for 16 hours. The reaction solution was filtered through celite, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title product (R)-5-(2-((1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)amino)-1H-imidazole-5-yl)pyrimidin-2-amine 301 mg, yield: 79.5%. MS m / z (ESI): 425.1 [M+1]
[0592] Embodiment 149
[0593] (R)-1-(2-aminopyrimidin-5-yl)-3-(1-(3-cyano-5,7-difluorobenzofuran-2-yl)-2,2,2-trifluoroethyl)urea
[0594]
[0595] first step
[0596] (R)-1-(3-Bromo-5,7-difluorobenzofuran-2-yl)-2,2,2-trifluoroethane-1-amine
[0597] (R)-1-(5,7-difluorobenzofuran-2-yl)-2,2,2-trifluoroethane-1-amine (300 mg, 1.19 mmol) and Br2 (203 mg, 1.25 mmol) were dissolved in glacial acetic acid (10 mL), and the reaction solution was heated to 80°C and stirred for 12 hours. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title product (R)-1-(3-bromo-5,7-difluorobenzofuran-2-yl)-2,2,2-trifluoroethane-1-amine 286 mg, yield: 72.5%. MS m / z (ESI): 330.0 [M+1]
[0598] Step 2
[0599] (R)-2-(1-amino-2,2,2-trifluoroethyl)-5,7-difluorobenzofuran-3-carbonitrile
[0600] (R)-1-(3-bromo-5,7-difluorobenzofuran-2-yl)-2,2,2-trifluoroethane-1-amine (286 mg, 0.867 mmol), zinc cyanide (305 mg, 2.60 mmol), tetrakistriphenylphosphine palladium (101 mg, 0.087 mmol) were dissolved in DMF (10 mL), the reaction solution was heated to 100°C, and stirred for 12 hours. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title product (R)-2-(1-amino-2,2,2-trifluoroethyl)-5,7-difluorobenzofuran-3-carbonitrile 144 mg, yield: 60.2%. MS m / z (ESI): 277.0 [M+1]
[0601] Step 3
[0602] (R)-1-(2-aminopyrimidin-5-yl)-3-(1-(3-cyano-5,7-difluorobenzofuran-2-yl)-2,2,2-trifluoroethyl)urea
[0603] Example 149 was prepared by referring to the synthetic method of Example 1. MS m / z (ESI): 413.1 [M+1].
[0604] Embodiment 156
[0605] (R)-1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-2-methylbenzofuran-3-yl)-2,2,2-trifluoroethyl)urea
[0606]
[0607] first step
[0608] 1-(5,7-Difluoro-2-methylbenzofuran-3-yl)-2,2,2-trifluoroethane-1-one
[0609] 5,7-difluoro-2-methylbenzofuran (100 mg, 0.595 mmol), titanium tetrachloride (113 mg, 0.595 mmol), trifluoroacetic anhydride (375 mg, 1.79 mmol) were dissolved in toluene (10 mL) and stirred at room temperature for 12 hours. Saturated ammonium chloride solution was added to the reaction solution to quench the reaction, extracted with ethyl acetate (20 mL × 3), combined organic phases, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain the title product 1-(5,7-difluoro-2-methylbenzofuran-3-yl)-2,2,2-trifluoroethane-1-one 110 mg, yield: 70.0%. MS m / z (ESI): 265.0 [M+1]
[0610] Step 2
[0611] (R)-1-(5,7-difluoro-2-methylbenzofuran-3-yl)-2,2,2-trifluoroethane-1-amine
[0612] 1-(5,7-difluoro-2-methylbenzofuran-3-yl)-2,2,2-trifluoroethane-1-one (110 mg, 0.416 mmol) and ammonium acetate (321 mg, 4.16 mmol) were dissolved in ethanol (5 mL), and the reaction solution was heated to 80 ° C and stirred for 12 hours. The reaction solution was cooled to room temperature, sodium cyanoborohydride (78 mg, 1.25 mmol) was added to the reaction solution, and the reaction was stirred at room temperature for 1 hour. Saturated ammonium chloride solution was added to the reaction solution to quench the reaction, and it was extracted with ethyl acetate (10 mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and then separated by chiral HPLC to obtain the title product (R)-1-(5,7-difluoro-2-methylbenzofuran-3-yl)-2,2,2-trifluoroethane-1-amine 46 mg, yield: 41.7%. MS m / z(ESI):266.1[M+1]
[0613] Step 3
[0614] (R)-1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-2-methylbenzofuran-3-yl)-2,2,2-trifluoroethyl)urea
[0615] Example 156 was prepared by referring to the synthetic method of Example 1. MS m / z (ESI): 402.1 [M+1].
[0616] Embodiment 159
[0617] 1-[(2-aminopyrimidin-5-yl)amino]-N-[(1R)-1-(6,8-difluoro-4-methyl-2H-chromen-3-yl)-2,2,2-
[0618] trifluoroethyl]methaneamide
[0619]
[0620] first step
[0621] 6,8-Difluoro-4-methyl-4H-chromene-3-carboxylic acid methyl ester
[0622] To a solution of 1-(3,5-difluoro-2-hydroxyphenyl)ethan-1-one (2.0 g, 11.6 mmol) in N,N-dimethylacetamide (20 mL), potassium carbonate (2.4 g, 17.4 mmol) and methyl 3-bromopropionate (2.1 g, 12.3 mmol) were added in sequence. The reaction solution was reacted at 25°C for 2 hours. The insoluble matter in the reaction solution was filtered, and 1,8-diazobispiro[5.4.0]undec-7-ene (1.77 g, 11.6 mmol) was added to the filtrate. The reaction solution was reacted at 100°C for 12 hours. 50 mL of water was added to the reaction solution, and the mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent system C to obtain 1.2 g of the title product, 6,8-difluoro-4-methyl-4H-chromene-3-carboxylic acid methyl ester, with a yield of 45.9%. MS m / z (ESI): 241.1 [M+1]
[0623] Step 2
[0624] (6,8-Difluoro-4-methyl-4H-chromen-3-yl)methanol
[0625] Methyl 6,8-difluoro-4-methyl-4H-chromene-3-carboxylate (430 mg, 1.79 mmol) was dissolved in tetrahydrofuran (9 mL), and lithium aluminum tetrahydride tetrahydrofuran solution (1.1 mL, 1.1 mmol, 1 M) was added at 0°C, and the mixture was reacted at 0°C for 2 hours. After the reaction was completed, saturated potassium carbonate solution (7 mL) and water (20 mL) were added to quench the reaction, and then extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system C to obtain 150 mg of the title product (6,8-difluoro-4-methyl-4H-chromene-3-yl)methanol, with a yield of 39.5%.
[0626] MS m / z(ESI):213.1[M+1]
[0627] Step 3
[0628] 6,8-Difluoro-4-methyl-4H-chromene-3-carbaldehyde
[0629] At room temperature, 2-iodoacylbenzoic acid (1.37 g, 4.9 mmol) was added to a solution of (6,8-difluoro-4-methyl-4H-chromen-3-yl)methanol (690 mg, 3.26 mmol) in acetonitrile (8 mL). After the reaction solution was stirred at 80°C for 2 hours, the insoluble matter in the reaction solution was filtered off, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent system C to obtain the title product 6,8-difluoro-4-methyl-4H-chromen-3-carbaldehyde (400 mg, yield: 58.4%). MS m / z (ESI): 211.1 [M+1].
[0630] Step 4
[0631] 1-(5,7-difluoro-3-methyl-1-benzofuran-2-yl)-2,2,2-trifluoroethan-1-ol
[0632] To a solution of 6,8-difluoro-4-methyl-4H-chromene-3-carboxaldehyde (650 mg, 3.1 mmol) in N,N-dimethylacetamide (10 mL) was added (trifluoromethyl)trimethylsilane (890 mg, 6.22 mmol) and potassium carbonate (210 mg, 1.55 mmol) at 0°C, and the reaction mixture was reacted at room temperature for 16 hours. After the reaction was completed, water (20 mL) was added to quench the reaction, and then extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography with eluent system C to obtain 600 mg of the title product 1-(5,7-difluoro-3-methyl-1-benzofuran-2-yl)-2,2,2-trifluoroethan-1-ol in a yield of 69.1%. MS m / z(ESI):281.1[M+1]
[0633] Step 5
[0634] 1-(6,8-Difluoro-4-methyl-4H-chromen-3-yl)-2,2,2-trifluoroethan-1-one
[0635] 2-Iodoacylbenzoic acid (580 mg, 2.1 mmol) was added to a solution of 1-(5,7-difluoro-3-methyl-1-benzofuran-2-yl)-2,2,2-trifluoroethan-1-ol (390 mg, 1.39 mmol) in acetonitrile (5 mL) at room temperature. After the reaction solution was stirred at 80°C for 2 hours, the insoluble matter in the reaction solution was filtered off, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent system C to obtain the title product 1-(6,8-difluoro-4-methyl-4H-chromen-3-yl)-2,2,2-trifluoroethan-1-one (280 mg, yield: 71.9%). MS m / z (ESI): 279.1 [M+1].
[0636] Step 6
[0637] 1-(6,8-Difluoro-4-methyl-4H-chromen-3-yl)-2,2,2-trifluoroethan-1-amine
[0638] 1-(6,8-difluoro-4-methyl-4H-chromen-3-yl)-2,2,2-trifluoroethan-1-one (350 mg, 1.21 mmol), hydroxylamine hydrochloride (585 mg, 8.48 mmol) and sodium acetate (993 mg, 12.1 mmol) in ethanol (5 mL) were reacted at 80°C for 16 hours. The reaction solution was then concentrated under reduced pressure, the residue was dissolved in methanol (5 mL), Raney nickel (50 mg) and 1 drop of ammonia were added, and the reaction solution was continued to react at room temperature under hydrogen (15 Psi) for 5 hours. After the reaction was completed, the insoluble matter in the reaction solution was filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography using eluent system C to obtain 300 mg of the title product 1-(6,8-difluoro-4-methyl-4H-chromen-3-yl)-2,2,2-trifluoroethan-1-amine, with a yield of 88.9%. MS m / z(ESI):280.1[M+1]
[0639] Step 7
[0640] 1-[(2-aminopyrimidin-5-yl)amino]-N-[1-(6,8-difluoro-4-methyl-2H-chromen-3-yl)-2,2,2-trifluoroethyl]methaneamide
[0641] To a solution of 1-(6,8-difluoro-4-methyl-4H-chromen-3-yl)-2,2,2-trifluoroethan-1-one (160 mg, 0.57 mmol) and triethylamine (150 mg, 1.70 mmol) in N,N-dimethylacetamide (3 mL) was added [(2-aminopyrimidin-5-yl)amino]methanoic acid phenyl ester (143 mg, 0.62 mmol), and the reaction solution was reacted at room temperature for 16 hours. After the reaction was completed, water (20 mL) was added to quench the reaction, and then extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using eluent system C to obtain 200 mg of the title product 1-[(2-aminopyrimidin-5-yl)amino]-N-[1-(6,8-difluoro-4-methyl-2H-chromen-3-yl)-2,2,2-trifluoroethyl]methaneamide, with a yield of 84.5%. MS m / z (ESI): 416.1 [M+1]
[0642] Step 8
[0643] 1-[(2-aminopyrimidin-5-yl)amino]-N-[(1R)-1-(6,8-difluoro-4-methyl-2H-chromen-3-yl)-2,2,2-
[0644] trifluoroethyl]methaneamide
[0645] 1-[(2-aminopyrimidin-5-yl)amino]-N-[1-(6,8-difluoro-4-methyl-2H-chromen-3-yl)-2,2,2-trifluoroethyl]methaneamide (200 mg, 0.48 mmol) was purified by chiral separation to give the title product 159 90 mg, yield: 45%. MS m / z (ESI): 416.1 [M+1]
[0646] Embodiment 182
[0647] N-{2-[(2-aminopyrimidin-5-yl)amino]-1-(4,4-difluorocyclohexyl)-2-oxylideneethyl}-5-fluoro-3-(trifluoromethyl)benzamide
[0648]
[0649] first step
[0650] ({2-[(2-aminopyrimidin-5-yl)amino]-1-(4,4-difluorocyclohexyl)-2-oxyylideneethyl}amino)methane acid
[0651] -2-methylpropan-2-yl ester
[0652] 2-(4,4-difluorocyclohexyl)-2-({[(2-methylpropan-2-yl)oxy]carbonyl}amino)acetic acid (200 mg, 0.68 mmol) was dissolved in 3 mL of N,N-dimethylacetamide, and O-(7-azabenzotriazol-1-yl)-, N,N',N N'-tetramethyluronium hexafluorophosphate (275 mg, 0.75 mmol), N,N-diisopropylethylamine (173 mg, 1.36 mmol), and pyrimidine-2,5-diamine (75 mg, 0.68 mmol) were added to the reaction system in sequence. The reaction solution was reacted at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography using eluent system C to obtain 121 mg of the title product ({2-[(2-aminopyrimidin-5-yl)amino]-1-(4,4-difluorocyclohexyl)-2-oxyylideneethyl}amino)methanoic acid-2-methylpropan-2-yl ester, yield: 46.2%. MS m / z (ESI): 386.2 [M+1]
[0653] Step 2
[0654] 2-Amino-N-(2-aminopyrimidin-5-yl)-2-(4,4-difluorocyclohexyl)acetamide
[0655] Dissolve ({2-[(2-aminopyrimidin-5-yl)amino]-1-(4,4-difluorocyclohexyl)-2-oxyylideneethyl}amino)methanoic acid-2-methylpropan-2-yl ester (120 mg, 0.31 mmol) in dichloromethane (3 mL), add trifluoroacetic acid (707 mg, 6.2 mmol) at 0°C, and react at 25°C for 2 hours. After the reaction is completed, add saturated potassium carbonate solution (7 mL) and water (20 mL) to quench the reaction, then extract with ethyl acetate (30 mL×3), combine the organic phases, wash with saturated sodium chloride solution (50 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain the title product 2-amino-N-(2-aminopyrimidin-5-yl)-2-(4,4-difluorocyclohexyl)acetamide 86 mg, yield: 97%. MS m / z(ESI):286.2[M+1]
[0656] Step 3
[0657] N-{2-[(2-aminopyrimidin-5-yl)amino]-1-(4,4-difluorocyclohexyl)-2-oxylideneethyl}-5-fluoro-3-(trifluoromethyl)benzamide
[0658] To a solution of 2-amino-N-(2-aminopyrimidin-5-yl)-2-(4,4-difluorocyclohexyl)acetamide (86 mg, 0.3 mmol) in dichloromethane (2 mL) was added 5-fluoro-3-(trifluoromethyl)benzoyl chloride (68 mg, 0.3 mmol) and triethylamine (0.04 mL, 1 mmol) at 0°C, and the reaction mixture was stirred at 20°C for 2 hours. After the reaction was completed, saturated potassium carbonate solution (5 mL) and water (10 mL) were added to quench the reaction, and then extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC to give the title product N-{2-[(2-aminopyrimidin-5-yl)amino]-1-(4,4-difluorocyclohexyl)-2-oxyylideneethyl}-5-fluoro-3-(trifluoromethyl)benzamide (19 mg, yield: 13.3%). MS m / z(ESI):476.1[M+1].
[0659] Embodiment 203
[0660] 2-amino-2-(2-aminopyrimidin-5-yl)-N-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-
[0661] (trifluoroethyl)acetamide
[0662]
[0663] first step
[0664] 2-Amino-2-(2-aminopyrimidin-5-yl)acetic acid
[0665] Disperse 2-aminopyrimidine-5-carboxaldehyde (200 mg, 1.62 mmol), KCN (317 mg, 4.86 mmol), and ammonium acetate (1.25 g, 16.20 mmol) in N,N-dimethylacetamide (10 mL) and stir at room temperature for 2 hours. Concentrate the reaction solution under reduced pressure, dissolve the residue in HCl (4 M in dioxane, 5 mL), and stir at room temperature for 3 hours. Concentrate the reaction solution under reduced pressure to obtain 196 mg of the title product 2-amino-2-(2-aminopyrimidin-5-yl)acetic acid, with a yield of 71.8%. MS m / z (ESI): 169.1 [M+1]
[0666] Step 2
[0667] 2-(tert-Butyloxycarbonyl)amino)-2-(2-((tert-Butyloxycarbonyl)amino)pyrimidin-5-yl)acetic acid
[0668] 203a (196 mg, 1.17 mmol), triethylamine (592 mg, 5.85 mmol), di-tert-butyl dicarbonate (766 mg, 3.51 mmol) were dissolved in dichloromethane (10 mL) and stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 342 mg of the title product 2-(tert-butoxycarbonyl)amino)-2-(2-((tert-butoxycarbonyl)amino)pyrimidin-5-yl)acetic acid, with a yield of 79.7%.
[0669] MS m / z(ESI):369.2[M+1]
[0670] Step 3
[0671] tert-Butyl (1-(2-(((tert-Butyloxycarbonyl)amino)pyrimidin-5-yl)-2-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)amino)-2-oxoethyl)carbamate
[0672] 203b (342 mg, 0.93 mmol), triethylamine (567 mg, 5.57 mmol), 1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethane-1-amine (246 mg, 0.93 mmol) and HATU (529 mg, 1.39 mmol) were dissolved in dichloromethane (10 mL) and stirred at room temperature for 1 hour. The reaction was quenched by adding saturated ammonium chloride solution, extracted with ethyl acetate (20 mL×3), the organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 401 mg of the title product (1-(2-(((tert-butyloxycarbonyl)amino)pyrimidin-5-yl)-2-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)amino)-2-oxoethyl)carbamic acid tert-butyl ester, yield: 70.2%. MS m / z(ESI):616.2[M+1]
[0673] Step 4
[0674] 2-amino-2-(2-aminopyrimidin-5-yl)-N-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-
[0675] (trifluoroethyl)acetamide
[0676] 203c (401 mg, 0.65 mmol) and HCl (4M in dioxane, 5 mL) were dissolved in dichloromethane (10 mL) and stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was dissolved in dichloromethane, washed once with saturated sodium bicarbonate solution, dried over anhydrous sodium sulfate, filtered, and the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 175 mg of the title product 2-amino-2-(2-aminopyrimidin-5-yl)-N-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)acetamide, with a yield of 64.7%.
[0677] MS m / z(ESI):416.1[M+1]
[0678] Embodiment 206
[0679] 3-amino-2-((1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)amino)imidazo[1,2-a]pyridine-6-sulfonamide
[0680]
[0681] first step
[0682] 2-Chloro-3-nitroimidazo[1,2-a]pyridine-6-sulfonamide
[0683] 2-Chloromidazo[1,2-a]pyridine-6-sulfonamide (300 mg, 1.30 mmol) was dissolved in a mixed solvent of nitric acid (10 mL) and sulfuric acid (10 mL), and stirred at room temperature for 2 hours. The reaction solution was diluted with water, extracted with dichloromethane (20 mL × 3), the organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title product 2-chloro-3-nitroimidazo[1,2-a]pyridine-6-sulfonamide 282 mg, yield: 78.7%. MS m / z (ESI): 277.0 [M+1]
[0684] Step 2
[0685] 2-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethylamino)-3-nitroimidazo[1,2-a]pyridine-6-sulfonamide
[0686] 206a (282 mg, 1.02 mmol), 1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethane-1-amine (270 mg, 1.02 mmol), and DIEA (527 mg, 4.08 mmol) were dissolved in DMSO (10 mL) and stirred at 80°C for 2 hours. The reaction solution was diluted with water, extracted with dichloromethane (20 mL×3), and the organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and the reaction solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 410 mg of the title product 2-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethylamino)-3-nitroimidazo[1,2-a]pyridine-6-sulfonamide, with a yield of 79.6%.
[0687] MS m / z(ESI):506.1[M+1]
[0688] Step 3
[0689] 3-amino-2-((1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)amino)
[0690] Imidazolo[1,2-a]pyridine-6-sulfonamide
[0691] 206b (410 mg, 0.81 mmol), tetrahydroxydiboron (218 mg, 2.43 mmol), and 4,4'-bipyridine (13 mg, 0.08 mmol) were dissolved in DMf (10 mL) and stirred at room temperature for 2 hours. The reaction solution was diluted with water, extracted with dichloromethane (20 mL×3), and the organic phases were combined, washed with saturated sodium chloride solution (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain the title product 3-amino-2-((1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl)amino)imidazo[1,2-a]pyridine-6-sulfonamide 311 mg, yield: 80.6%. MS m / z(ESI):476.1[M+1]
[0692]
[0693]
[0694]
[0695]
[0696]
[0697]
[0698]
[0699]
[0700]
[0701]
[0702]
[0703]
[0704]
[0705]
[0706]
[0707]
[0708]
[0709]
[0710]
[0711]
[0712] Biological test evaluation
[0713] The present invention is further described and explained below in conjunction with test examples, but these embodiments are not intended to limit the scope of the present invention.
[0714] Test Example 1: Experiment on the inhibitory activity of the compounds of the present invention on PI3Kα mutant and wild-type kinases.
[0715] Purpose of the experiment: The purpose of this test case is to test the inhibitory activity of the compound against PI3Kα mutant and wild-type kinases.
[0716] Experimental instruments: Centrifuge (5810R) was purchased from Eppendorf, pipettes were purchased from Eppendorf or Rainin, and microplate reader was purchased from BioTek, USA, model SynergyH1 full-function microplate reader.
[0717] Experimental method: This experiment uses Promega's ADP-Glo lipid kinase assay (Promega # V9102). The lipid kinase PI3Kα catalyzes the reaction in the presence of substrate PIP2:3PS and ATP. ATP generates ADP. The activity of lipid kinase is characterized by measuring the content of ADP in the reaction, and the half inhibitory concentration IC of the compound on the inhibition of PI3Kα kinase activity is obtained. 50 .
[0718] The specific experimental operations are as follows:
[0719] Kinase reaction was performed in a white 384-well plate (Perkin Elmer #6007299). 2 μL of different concentrations of compounds diluted with 1% DMSO in ddH2O were added to each well. 2 μL of 1% DMSO in ddH2O was added to the positive control wells. Then, 2 μL of 0.01-1 μg / mL PI3Kα mutant (H1047R, E545K, E542K) and wild-type kinase solutions diluted with 5× kinase buffer (HEPES 250 mM, MgCl2 15 mM, NaCl 250 mM, BSA 0.05%) were added to each well. 2 μL of 5× kinase buffer was added to the negative control wells. 4 μL of 50 μM substrate PIP2:3PS (Promega #V1701) prepared with 10× Dilution buffer and ddH2O was added to all wells. Finally, 2 μL of 50-100 μM PI3Kα diluted with water was added. The reaction was initiated with ATP solution. After reacting at room temperature for 90 to 120 minutes, 10 μL ADP-Glo Reagent (containing 10 mM MgCl2) was added to each well and reacted at room temperature for 60 minutes to remove excess ATP in the reaction. Then 20 μL Kinase Detection Reagent was added to each well. After reacting at room temperature in the dark for 20 minutes, the chemiluminescence value was detected using a BioTek Synergy H1 microplate reader.
[0720]
[0721] Experimental data processing method:
[0722] The percentage inhibition data of the wells treated with the compound were calculated by the positive control wells (DMSO control wells) and the negative control wells (no kinase added) on the plate {% inhibition rate = 100-[(test compound value-negative control value)] / (positive control value-negative control value)×100}. GraphPad prism was used to fit the different concentrations and the corresponding percentage inhibition rate data to a 4-parameter nonlinear logistic formula to calculate the IC 50 value.
[0723] Experimental conclusion:
[0724] The above scheme shows that the compounds of the present invention show about 0.001nM to 100nM (IC 50 )'s biological activity.
[0725] In some embodiments, the IC values of the compounds of the invention for PI3Kα kinase activity are 50 The IC values of the compounds listed in the present invention are less than about 100 nM, the preferred compounds are less than about 50 nM, the more preferred compounds are less than about 10 nM, the further preferred compounds are less than about 1 nM, and the further preferred compounds among the compounds listed in the present invention are less than 10 nM or even less than about 1 nM. 50 Value inhibitory activity.
[0726] Test Example 2: Determination of the inhibitory activity of the compounds of the present invention on PI3Kβ / γ / δ kinases
[0727] Experimental purpose: The purpose of this test case is to test the inhibitory activity of the compound on PI3Kβ / γ / δ kinase.
[0728] Experimental instruments: Centrifuge (5810R) was purchased from Eppendorf, pipettes were purchased from Eppendorf or Rainin, and microplate reader was purchased from BioTek, USA, model SynergyH1 full-function microplate reader.
[0729] Experimental method: This experiment uses Promega's ADP-Glo lipid kinase assay (Promega # V9102). Lipid kinase PI3Kβ / γ / δ undergoes a catalytic reaction in the presence of substrate PIP2:3PS and ATP. ATP generates ADP. The activity of lipid kinase is characterized by measuring the content of ADP in the reaction, and the half inhibitory concentration IC of the compound on the inhibition of PI3Kβ / γ / δ kinase activity is obtained. 50 .
[0730] The specific experimental operations are as follows:
[0731] Kinase reaction was carried out in a white 384-well plate (Perkin Elmer #6007299). 2 μL of different concentrations of compounds diluted with 1% DMSO in ddH2O were added to each well. 2 μL of 1% DMSO in ddH2O was added to the positive control wells. Then, 2 μL of 0.25-1 μg / mL PI3K kinase solution diluted with 5× kinase buffer (HEPES 250 mM, MgCl2 15 mM, NaCl 250 mM, BSA 0.05%) was added to each well. 2 μL of 5× kinase buffer was added to the negative control wells. 4 μL of 50 μM substrate PIP2:3PS (Promega #V1701) prepared with 10× Dilution buffer and ddH2O was added to all wells. Finally, 2 μL of 50-100 μM ATP solution diluted with water was added to start the reaction. After reacting at room temperature for 90-120 minutes, 10 μL of ADP-Glo Reagent (containing 10 mM MgCl2) at room temperature for 60 minutes to remove excess ATP in the reaction, then add 20 μL Kinase Detection Reagent to each well, react at room temperature in the dark for 20 minutes, and then use BioTek Synergy H1 microplate reader to detect chemiluminescence value.
[0732] Enzyme name Part Number Enzyme reaction concentration Enzyme reaction time ATP concentration PI3Kβ Carna#11-102 1 μg / mL 90min 100μM PI3Kγ Thermofisher#PV4786 0.5 μg / mL 120min 50μM PI3Kδ Carna#11-103 0.25 μg / mL 90min 100μM
[0733] Experimental data processing method:
[0734] The percentage inhibition data of the wells treated with the compound were calculated by the positive control wells (DMSO control wells) and the negative control wells (no kinase added) on the plate {% inhibition rate = 100-[(test compound value-negative control value)] / (positive control value-negative control value)×100}. GraphPad prism was used to fit the different concentrations and the corresponding percentage inhibition rate data to a 4-parameter nonlinear logistic formula to calculate the IC 50 value.
[0735] Experimental conclusion:
[0736] The above scheme shows that the compounds of the present invention show about 1nM to 10000nM (IC 50 )'s biological activity.
[0737] In some embodiments, the IC values of the compounds of the invention for PI3K kinase activity are 50 The IC values of the compounds listed in the present invention are greater than about 10 nM, the preferred compounds are greater than about 100 nM, the more preferred compounds are greater than about 1000 nM, the further preferred compounds are greater than about 1000 nM, or even greater than about 10000 nM.50 Value suppression.
[0738] Test Example 3: Determination of the Proliferation Inhibitory Effect of the Compounds of the Invention on PI3Kα Mutant Cancer Cells
[0739] Experimental purpose: The purpose of this test example is to test the activity of the compound in inhibiting the proliferation of PI3Kα mutant cancer cells HCC1954 (H1047R), HGC-27 (E542K) and MKN1 (E545K).
[0740] Experimental instruments: Centrifuge (5702R) was purchased from Eppendorf, CO2 incubator was purchased from Thermo, biosafety cabinet was purchased from Shanghai Boxun, pipette was purchased from Eppendorf or Rainin, and microplate reader was purchased from BioTek, USA, model SynergyH1 full-function microplate reader.
[0741] Experimental methods: The Cell Titer-Glo method was used to detect the inhibitory effect of the compounds on the proliferation of PI3Kα mutant cancer cell lines HCC1954, HGC-27 and MKN1. The cell lines were cultured in RPMI 1640 medium (Gibco#22400089) containing 10% FBS (Gibco#10091148) and 1% P / S (Hyclone#SV30010) at 37°C and 5% CO2. When the cells grow to a certain degree of confluence, the cells are collected and the cell density is adjusted after counting. The cells are seeded at a density of 1000-10000 cells / well in a white 96-well plate (Corning#3610), placed in a 37°C, 5% CO2 incubator for overnight culture, and the prepared compound solutions of different concentrations are added. At the same time, corresponding solvent controls are set up. After continuing to be cultured in a 37°C, 5% CO2 incubator for 72 to 144 hours, the cell plate and its contents are equilibrated to room temperature, 20-100 μL Cell Titer-Glo solution (Promega#G7573) is added to each well, shaken and mixed, incubated at room temperature in the dark for 10 minutes, and the chemiluminescence value is detected using BioTek's SynergyH1 microplate reader.
[0742] Experimental data processing method:
[0743] The percentage inhibition data of the wells treated with the compound were calculated by the vehicle control wells on the plate {% inhibition rate = 100-(test compound value / vehicle control value) × 100}. GraphPad prism was used to fit the different concentrations and the corresponding percentage inhibition rate data to a 4-parameter nonlinear logistic formula to calculate the IC 50 value.
[0744] Experimental conclusion:
[0745] The above schemes show that the compounds of the present invention have an inhibitory activity against the proliferation of PI3Kα mutant cancer cells HCC1954 (H1047R), HGC-27 (E542K) and MKN1 (E545K) of about 10 nM to 10000 nM (IC 50 )'s biological activity.
[0746] In some embodiments, the IC values of the compounds prepared by the present invention for the inhibitory activity of the test compounds on the proliferation of PI3Kα mutant cancer cells HCC1954 (H1047R), HGC-27 (E542K) and MKN1 (E545K) are 50 The IC values of the compounds are less than about 10000 nM, preferably less than about 5000 nM, more preferably less than about 1000 nM, more preferably less than about 500 nM, and even more preferably less than 100 nM. 50 Value inhibitory activity.
Claims
1. A compound represented by general formula (I), its stereoisomer or a pharmaceutically acceptable salt thereof: in: is a single bond or a double bond; M1 and M2 are each independently selected from a bond, CR 11 NR 11 , CR 22 R 33 , O or S; L1 is selected from a bond, NR 44 NR 44 C(O)NR 55 NR 44 C(O)NR 55 (CR 66 R 77 ) n1 NR 44 S(O) n1 NR 55 NR 44 PR 66 (O) n1 NR 55 NR 44 C(=NR 77 )NR 55 、OC(O)NR 55 NR 44 C(O)O、NR 44 C(=S)NR 55 NR 44 C(O) n1 (CR 55 R 66 ) n2 NR 44 (C 3-8 Cycloalkyl)(NR 55 ) n2 ,(NR 55 ) n2 NR 44 (3-8 membered heterocyclic group)(NR 55 ) n2 NR 44 (C 6-10 Aryl)(NR 55 ) n2 NR 44 (5-8 membered heteroaryl)(NR 55 ) n2 NR 44 C(O) n1 (CR 55 R 66 )NR 77 、C(O)NR 44 NR 55 C(O), C(O)NR 44 (CR 55 R 66 )C(O)NR 77 or NR 44 (CR 55 R 66 )C(O)NR 77 ; Ring A and Ring B are each independently selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group; R2 is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 1-6 Alkylthio, C 1-6 Halogenated alkylthio, halogenated thio, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group; Alternatively, any two R2 are linked to the adjacent carbon atoms to form a C 3-12 Cycloalkyl or 3-12 membered heterocyclic group, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl; R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; R 11 , R 22 or R 33 is present or absent, and when present is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -C(O)R 1a 、-NR 2a C(O)R 3a or -C(R 1a R 2a ) t1 R 3a , optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group; R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; Or, R 44 , R 55 , R 66 or R 77 Any two of them are linked to the adjacent carbon atoms to form a C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; Alternatively, =N on L1 is linked to an atom on ring B to form a 3-12 membered heterocyclic group or a 5-12 membered heteroaryl group, which is optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; R 1a , R 2a or R 3a are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group; R aa , R bb or R cc are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group; t1 is 0, 1, or 2; m is 0, 1 or 2; n is 0, 1 or 2; p is 0, 1, or 2; r is 1 or 2; n1 is 0, 1 or 2; n2 is 0, 1 or 2; n3 is 0, 1 or 2; and m1 is 0, 1 or 2; Or as shown in general formula (IA-1) or (IA-2): Or as shown in general formula (IB): Ring B is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl is substituted with one or more substituents; Ring C is selected from C 5-8 Cycloalkyl, 5-8 membered heterocyclic group, C 6-10 Aryl or 5-8 membered heteroaryl, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl, substituted by one or more substituents; ring C is preferably C 5-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, which may be further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl is substituted with one or more substituents; Or as shown in the general formula (IC-1) or (IC-2): M2 is independently selected from NR 11 , CR 22 R 33 , O or S; Ring B1 is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl, wherein one or more substituents are substituted; preferably ring B is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring B is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 The cycloalkyl group is substituted with one or more substituents selected from N, O or S atoms, 3-6 membered heterocyclic group, phenyl group or 5-8 membered heteroaryl group; Ring D is selected from 3-12 membered heterocyclic groups or 5-12 membered heteroaryl groups, optionally substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 The ring D is preferably substituted with one or more substituents of a deuterated alkyl group; the ring D preferably contains 1-3 3-10 membered heterocyclic groups selected from N, O or S atoms or 1-3 5-10 membered heteroaryl groups selected from N, O or S atoms, optionally substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The ring D is preferably substituted with one or more substituents of a deuterated alkyl group; the ring D is more preferably substituted with a 3-8 membered heterocyclic group containing 1-3 selected from N, O or S atoms or a 5-8 membered heteroaryl group containing 1-3 selected from N, O or S atoms, optionally substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 substituted with one or more substituents of a deuterated alkyl group; When M2 is 0, Not for Or as shown in the general formula (IC-11), (IC-12), (IC-13) or (IC-14): in: X1~X 17 Each independently selected from C(O), CR X1 , CR X1 R X2 , N, NR X1 , O or S; M3~M 11 Each independently selected from C(O), CR X1 , CR X1 R X2 , N, NR X1 , O or S; R X1 or R X2 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group; Or as shown in the general formula (ID) or (ID'): Or as shown in the general formula (ID-1), (ID-2), (ID-3), (ID-4), (ID-5), (ID-6), (ID-7), (ID-8), (ID-9), (ID-10) or (ID-14): M2 are each independently selected from O or S; Or as shown in the general formula (ID-11): Ring C1 is present or absent, and when present is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; R q are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group; u is 0, 1, 2, or 3; Or as shown in the general formula (ID-12): Two R2 are linked to the adjacent carbon atom to form C 3-10 Cycloalkyl or 3-10 membered heterocyclic group, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 One or more substituents in the alkyl group are substituted; Preferably, two R2 are linked to the adjacent carbon atom to form a C 3-8 Cycloalkyl or 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 One or more substituents in the alkyl group are substituted; More preferably, two R2 are linked to the adjacent carbon atom to form a C 3-6 Cycloalkyl or 3-6 membered heterocyclic group containing 1-3 N, O or S atoms, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 One or more substituents in the alkyl group are substituted; Further preferably, two R2 are linked to the connected carbon atom to form a cyclopropyl, cyclobutyl or cyclopentyl group, which may be further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl; Or as shown in the general formula (ID-13): M2 are each independently selected from O or S; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 Alkyl, optionally substituted with hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group; R2 is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 Alkyl, optionally substituted with hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 substituted with one or more substituents of a deuterated alkyl group; Alternatively, two R2 are linked to the adjacent carbon atom to form a C 3-6 Cycloalkyl or 3-6 membered heterocyclic group containing 1-3 N, O or S atoms, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 One or more substituents in the alkyl group are substituted; R 11 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl, 5-10 membered heteroaryl containing 1-3 N, O or S atoms, -C(O)R 1a 、-NR 2a C(O)R 3a or -C(R 1a R 2a ) t1 R 3a , optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R 11 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl, 5-8 membered heteroaryl containing 1-3 N, O or S atoms, -C(O)R 1a 、-NR 2a C(O)R 3a or -C(R 1a R 2a ) t1 R 3a , optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 More preferably, R 11 is selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, propyl, vinyl, allyl, propenyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, propoxy, fluorinated methoxy, fluorinated ethoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl, cyano-substituted methyl, cyano-substituted ethyl, cyano-substituted propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, formyl, acetyl, Optionally substituted with one or more substituents selected from the group consisting of hydrogen, hydroxy, fluorine, chlorine, bromine, cyano, amino, methyl, ethyl, propyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, and difluoromethyl; R 1a , R 2a or R 3a are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 N, O or S atoms, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R 1a , R 2a or R 3a are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 N, O or S atoms, C 6-10 Aryl or 5-8 membered heteroaryl containing 1-3 N, O or S atoms, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 More preferably, R 1a , R 2a or R 3a each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, propyl, vinyl, allyl, propenyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, propoxy, fluorine-substituted methoxy, fluorine-substituted ethoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl, cyano-substituted methyl, cyano-substituted ethyl or cyano-substituted propyl; R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl, 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 , the C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl, 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl, 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, substituted by one or more substituents; Preferably, R3 is each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, propyl, vinyl, allyl, propenyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, propoxy, fluorinated methoxy, fluorinated ethoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl, cyano-substituted methyl, cyano-substituted ethyl, cyano-substituted propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, formyl, acetyl, -CH2C(O)NH2, -CH2S(O)2NH2, -NHC(O)CF3, -P(O)(CH3)2, Optionally substituted with one or more substituents selected from the group consisting of hydrogen, hydroxy, fluorine, chlorine, bromine, cyano, amino, methyl, ethyl, propyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, and difluoromethyl; R aa , R bb or R cc are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 Alkyl, optionally substituted with hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 substituted with one or more substituents of a deuterated alkyl group; Preferably, R aa , R bb or R cc each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxy, cyano, nitro, methyl, ethyl, propyl, vinyl, allyl, propenyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, propoxy, fluorine-substituted methoxy, fluorine-substituted ethoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl, cyano-substituted methyl, cyano-substituted ethyl or cyano-substituted propyl, optionally substituted with one or more substituents selected from hydrogen, hydroxy, fluorine, chlorine, bromine, cyano, amino, methyl, ethyl, propyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl or difluoromethyl; R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 is substituted with one or more substituents of a deuterated alkyl group; More preferably, R 31 or R 32 are each independently selected from deuterium, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, is substituted with one or more substituents; The conditions are: (1) When M2 is O, R1 is F, R2 is H or trifluoromethyl, and R3 is not -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 When R 11 Not methyl; Or as shown in general formula (IE) or (IE-1): M2 is selected from NR 11 , CR 22 R 33 , O or S; Ring E is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; Preferably, ring E is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 substituted by one or more substituents of aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S; Or as shown in general formula (IF) or (IF-1): Ring B1 is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl; preferably ring B1 is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring B1 is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 The cycloalkyl group is substituted with one or more substituents selected from N, O or S atoms, 3-6 membered heterocyclic group, phenyl group or 5-8 membered heteroaryl group; Ring D is selected from 3-12 membered heterocyclic groups or 5-12 membered heteroaryl groups, optionally substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 The ring D is preferably substituted with one or more substituents of a deuterated alkyl group; the ring D preferably contains 1-3 3-10 membered heterocyclic groups selected from N, O or S atoms or 1-3 5-10 membered heteroaryl groups selected from N, O or S atoms, optionally substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 The ring D is preferably substituted with one or more substituents of a deuterated alkyl group; the ring D is more preferably substituted with a 3-8 membered heterocyclic group containing 1-3 selected from N, O or S atoms or a 5-8 membered heteroaryl group containing 1-3 selected from N, O or S atoms, optionally substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 substituted with one or more substituents of a deuterated alkyl group; Or as shown in general formula (IG): Ring B5 is selected from 3-10 membered heterocyclic groups, which may be further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring B5 is selected from a 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, and optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 More preferably, ring B5 is selected from a 5-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, which may be further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; further preferably, ring B5 is selected from Optionally, it may be further substituted with one or more substituents selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl.
2. A compound represented by general formula (II) or (III), its stereoisomer or a pharmaceutically acceptable salt thereof: M2 is selected from NR 11 , O, S or CR 22 R 33 ; Ring A2 and Ring B2 are each independently selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; Ring C2 is present or absent, and when present is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; R2 is selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -(CH2) n4 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n4 C(O)NR 31 R 32 、-(CH2) n4 P(O)R 31 R 32 、-(CH2) n4 P(O)2R 31 or -(CH2) n4 S(O) m4 R 32 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; R 11 , R 22 or R 33 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; When ring A2 is When , ring B2 is not a benzene ring; m2-m4 are each independently 0, 1, 2 or 3; and n4 is 0, 1 or 2; Ring A3 is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12aryl or 5-12 membered heteroaryl is substituted with one or more substituents; Ring B3 is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; Ring C3 is present or absent, and when present is selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; m5-m8 are each independently 0, 1, 2 or 3; and n5 is 0, 1 or 2.
3. A compound represented by general formula (IV), its stereoisomer or a pharmaceutically acceptable salt thereof: in: is a single bond or a double bond; X1 to X4 are each independently selected from a bond, N, NR x1 , C, CR x1 , CR x1 R x2 , O or S; L1 is selected from a bond, NR 44 NR 44 C(O)NR 55 NR 44 S(O) n1 NR 55 NR 44 PR 66 (O) n1 NR 55 NR 44 C(=NR 77 )NR 55 、OC(O)NR 55 NR 44 C(O)O、NR 44 C(=S)NR 55 NR 44 C(O) n1 (CR 55 R 66 ), NR 44 (C 5-8 Cycloalkyl)(NR 55 ) n2 ,(NR 55 ) n2 NR 44 (5-8 membered heterocyclic group)(NR 55 ) n2 NR 44 (C 6-10 Aryl)(NR 55 ) n2 NR 44 (5-8 membered heteroaryl)(NR 55 ) n2 or NR 44 C(O) n1 (CR 55 R 66 )NR 77 ; Ring A and Ring B are each independently selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; R2 is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group; R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -(CH2) n6 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n6 C(O)NR 31 R 32 、-(CH2) n6 P(O)R 31 R 32 、-(CH2) n6 P(O)2R 31 or -(CH2) n6 S(O) m9 R 32 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; R x1 or R x2 is present or absent, and when present is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group; Or, R 55 , R 66 Linked to the carbon atom to form C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; Alternatively, =N on L1 is linked to an atom on ring B to form a 3-12 membered heterocyclic group or a 5-12 membered heteroaryl group, which is optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; m9 is 0, 1, or 2; n6 is 0, 1 or 2; t is 0, 1, or 2; v is 1 or 2; and w is 0, 1, or 2; Or further as shown in general formula (IV-1), (IV-2), (IV-3) or (IV-4):
4. A compound represented by general formula (V) or (VI), a stereoisomer thereof or a pharmaceutically acceptable salt thereof: in: M2 and M1 are each independently selected from a bond, NR 11 , CR 11 , CR 22 R 33 , O or S; L1 is selected from a bond, NR 44 NR 44 C(O)NR 55 NR 44 C(O)NR 55 (CR 66 R 77 ) n1 NR 44 S(O) n1 NR 55 NR 44 PR 66 (O) n1 NR 55 NR 44 C(=NR 77 )NR 55 、OC(O)NR 55 NR 44 C(O)O、NR 44 C(=S)NR 55 NR 44 C(O) n1 (CR 55 R 66 ) n2 NR 44 (C 3-8 Cycloalkyl)(NR 55 ) n2 ,(NR 55 ) n2 NR 44 (3-8 membered heterocyclic group)(NR 55 ) n2 NR 44 (C 6-10 Aryl)(NR 55 ) n2 NR 44 (5-8 membered heteroaryl)(NR 55 ) n2 or NR 44 C(O) n1 (CR 55 R 66 )NR 55 ; Ring A and Ring B are each independently selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group; R2 is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; Alternatively, any two R2 are linked to the adjacent carbon atoms to form a C 3-12 Cycloalkyl or 3-12 membered heterocyclic group, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; R 11 , R 22 or R 33 is present or absent, and when present is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -C(O)R 1a 、-NR 2a C(O)R 3a or -C(R 1a R 2a ) t1 R 3a , optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; Or, R 44 , R 55 , R 66 or R 77 Any two of them are linked to the adjacent carbon atoms to form a C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; Alternatively, =N on L1 is linked to an atom on ring B to form a 3-12 membered heterocyclic group or a 5-12 membered heteroaryl group, which is optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group; R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group; R 1a , R 2a or R 3a are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; R aa , R bb or R cc are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group; t1 is 0, 1, or 2; m is 0, 1 or 2; n is 0, 1 or 2; p is 0, 1, or 2; r is 1 or 2; n1 is 0, 1 or 2; n2 is 0, 1 or 2; n3 is 0, 1 or 2; and m1 is 0, 1, or 2.
5. A compound represented by general formula (VII), a stereoisomer thereof or a pharmaceutically acceptable salt thereof: in: Ring A and Ring B are each independently selected from C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl, 5-12 membered heteroaryl, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 , the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; Or, R 44 , R 55 , R 66 or R 77 Any two of them are linked to the adjacent carbon atoms to form a C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 aryl or 5-12 membered heteroaryl is substituted with one or more substituents; R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 substituted with one or more substituents of a deuterated alkyl group; R aa , R bb or R cc are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Deuterated alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Hydroxyalkyl, cyano substituted C 1-6 Alkyl, C 3-12 Cycloalkyl, 3-12 membered heterocyclic group, C 6-12 Aryl or 5-12 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 is substituted with one or more substituents of a deuterated alkyl group; m is 0, 1 or 2; p is 0, 1, or 2; m1 is 0, 1 or 2; and n3 is 0, 1 or 2.
6. The compound of general formula (ID) or (ID') according to claim 1, its stereoisomer or a pharmaceutically acceptable salt thereof, wherein: R2, R 44 or R 55 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 Alkyl, optionally substituted with hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 substituted with one or more substituents of a deuterated alkyl group; Preferably, R2, R 44 or R 55 each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, propyl, vinyl, allyl, propenyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, propoxy, fluorine-substituted methoxy, fluorine-substituted ethoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl, cyano-substituted methyl, cyano-substituted ethyl, cyano-substituted propyl; The condition is that R2, R 44 or R 55 At least one of the groups is a hydroxyl group.
7. The compound according to any one of claims 1 to 5, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: M1 and M2 are each independently selected from a bond, NR 11 , CR 11 , CR 22 R 33 , O or S; R 11 , R 22 or R 33 is present or absent, and when present is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -C(O)R 1a 、-NR 2a C(O)R 3a or -C(R 1a R 2a ) t1 R 3a , optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 substituted with one or more substituents of a deuterated alkyl group; Preferably, R 11 , R 22 or R 33 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl, 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, -C(O)R 1a 、-NR 2a C(O)R 3a or -C(R 1a R 2a ) t1 R 3a , which may be further substituted with one or more substituents selected from deuterium, oxo, thioxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl; R 1a , R 2a or R 3a are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 substituted with one or more substituents of a deuterated alkyl group; Preferably, R 1a , R 2a or R 3a are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-6 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or a 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, which may be further substituted with one or more substituents selected from deuterium, oxo, thio, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl; L1 is selected from NR 44 NR 44 C(O)NR 55 NR 44 S(O) n1 NR 55 NR 44 PR 66 (O) n1 NR 55 NR 44 C(=NR 77 )NR 55 、OC(O)NR 55 NR 44 C(O)O、NR 44 C(=S)NR 55 NR 44 C(O) n1 (CR 55 R 66 ) n2 NR 44 (C 5-8 Cycloalkyl)(NR 55 ) n2 ,(NR 55 ) n2 NR 44 (5-8 membered heterocyclic group)(NR 55 ) n2 NR 44 (C 6-10 Aryl)(NR 55 ) n2 NR 44 (5-8 membered heteroaryl)(NR 55 ) n2 NR 44 C(O) n1 (CR 55 R 66 )NR 77 、C(O)NR 44 NR 55 C(O), C(O)NR 44 (CR 55 R 66 )C(O)NR 77 or NR 44 (CR 55 R 66 )C(O)NR 77 ; R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, hydroxy, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R 44 , R 55 , R 66 or R 77 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 substituted with one or more substituents of a deuterated alkyl group; Alternatively, the =N on L1 is linked to an atom on ring B to form a 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S or a 5-10 membered heteroaryl group containing 1-3 atoms selected from N, O or S, which is optionally substituted by hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 substituted with one or more substituents of a deuterated alkyl group; Ring A is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring A is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring A is selected from cyclopentyl, cyclohexyl, benzene ring, pyridine ring, pyrimidine ring, pyrazine, Optionally, it may be further substituted with one or more substituents selected from deuterium, oxo, thioxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl; Ring B is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring B is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring B is selected from benzene ring, pyridine ring, pyrimidine ring, thiazole, Optionally, it may be further substituted with one or more substituents selected from deuterium, oxo, thioxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl; Ring C is selected from C 5-10 aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl, substituted by one or more substituents; Ring C is preferably Pyridine or pyrimidine, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 substituted by one or more substituents of aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S; The ring fused to ring D and ring B1 is selected from C 6-10 Cycloalkyl, 6-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-12 aryl or 6-12 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S; preferably, the ring fused with ring D and ring B1 is selected from C 5-6 Cycloalkyl C 5-6 cycloalkyl, 5-6-membered heterocyclic radical containing 1-3 selected from N, O or S atoms and 5-6-membered heterocyclic radical containing 1-3 selected from N, O or S atoms, naphthyl, 5-6-membered heterocyclic radical containing 1-3 selected from N, O or S atoms and phenyl, 5-6-membered heterocyclic radical containing 1-3 selected from N, O or S atoms and 5-6-membered heteroaryl containing 1-3 selected from N, O or S atoms, phenyl and 5-6-membered heteroaryl containing 1-3 selected from N, O or S atoms, 5-6-membered heteroaryl containing 1-3 selected from N, O or S atoms and phenyl, or 5-6-membered heteroaryl containing 1-3 selected from N, O or S atoms and 5-6-membered heteroaryl containing 1-3 selected from N, O or S atoms and 5-6-membered heteroaryl containing 1-3 selected from N, O or S atoms, which may be further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, the ring fused with ring D and ring B1 is selected from Optionally, it may be further substituted with one or more substituents selected from hydrogen, deuterium, oxo, thioxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl; Ring E is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; preferably, ring E is selected from Optionally, it may be further substituted with one or more substituents selected from hydrogen, deuterium, oxo, thioxo, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl; Ring A2 or Ring B2 are each independently selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring A2 or ring B2 are each independently selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring A2 or ring B2 are each independently selected from C 3-6 Cycloalkyl, 5-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; further preferably, ring A2 or ring B2 are each independently selected from benzene ring, pyridine, Optionally, it may be further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methanesulfonyl, cyclopropyl, cyclobutyl or azetidinyl; Alternatively, ring C2 is present or absent, and when present is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring C2 is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring C2 is selected from C 3-6 Cycloalkyl, 5-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; further preferably, ring C2 is selected from cyclopropyl, cyclobutyl or azetidinyl, optionally further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl; Ring B3 is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring B3 is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring B3 is selected from C 3-6 Cycloalkyl, 5-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S; further preferably, ring B3 is selected from benzene ring, pyridine, Optionally, it may be further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, methanesulfonyl, cyclopropyl, cyclobutyl or azetidinyl; Alternatively, ring C3 is present or absent, and when present is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring C3 is independently selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring C3 is selected from C 3-6 Cycloalkyl, 5-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; further preferably, ring C3 is selected from cyclopropyl, cyclobutyl or azetidinyl, optionally further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl; Alternatively, Ring A3 is selected from C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl; preferably, ring A3 is selected from C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; more preferably, ring A3 is selected from C 3-6 Cycloalkyl, 5-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl or 5-6 membered heteroaryl containing 1-3 atoms selected from N, O or S is substituted with one or more substituents; further preferably, ring A3 is selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and optionally may be further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl; R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R1 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 More preferably, R1 is independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, propyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl, oxirane, epoxypropyl or epoxybutyl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 substituted with one or more substituents of a deuterated alkyl group; R2 is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 1-3 Alkylthio, C 1-3 Halogenated alkylthio, halogenated thio, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R2 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 More preferably, R2 is independently selected from hydrogen, deuterium, hydroxyl, halogen, cyano, amino, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; Alternatively, two R2 are linked to the adjacent carbon atom to form a C 3-10 Cycloalkyl or 3-10 membered heterocyclic group, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 One or more substituents in the alkyl group are substituted; Preferably, two R2 are linked to the adjacent carbon atom to form a C 3-8 Cycloalkyl or 3-8 membered heterocyclic group containing 1-3 N, O or S atoms, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 One or more substituents in the alkyl group are substituted; More preferably, two R2 are linked to the adjacent carbon atom to form a C 3-6 Cycloalkyl or 3-6 membered heterocyclic group containing 1-3 N, O or S atoms, optionally further substituted by hydrogen, deuterium, oxo, thio, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 One or more substituents in the alkyl group are substituted; Further preferably, two R2 are linked to the connected carbon atom to form a cyclopropyl, cyclobutyl or cyclopentyl group, which may be further substituted with one or more substituents selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl or trifluoroethyl; R3 is independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 , the C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group, C 6-10 aryl or 5-10 membered heteroaryl is substituted with one or more substituents; Preferably, R3 is each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 aryl, 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 ,, the C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl, 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 substituted by one or more substituents of aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S; More preferably, R3 is each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, amino, hydroxyl, cyano, nitro, methyl, ethyl, propyl, vinyl, allyl, propenyl, ethynyl, propynyl, propargyl, deuterated methyl, deuterated ethyl, deuterated propyl, fluoromethyl, fluoroethyl, trifluoromethyl, difluoromethyl, methoxy, ethoxy, propoxy, fluorine-substituted methoxy, fluorine-substituted ethoxy, trifluoromethoxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, 2-hydroxypropyl, cyano-substituted methyl, cyano-substituted ethyl, cyano-substituted propyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, formyl, acetyl, -CH2C(O)NH2, -CH2S(O)2NH2, -NHC(O)CF3, -P(O)(CH3)2, -(CR aa R bb ) n3 C(O)R 31 、N=S=OR 31 R 32 、-(CH2) n3 C(O)NR 31 R 32 、-(CH2) n3 P(O)R 31 R 32 、-(CH2) n3 P(O)2R 31 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 (NR 31 )C(O)R 32 、-(CR aa R bb ) n3 S(O)(=NR cc )R 32 or -(CR aa R bb ) n3 S(O) m1 R 32 ,, optionally further substituted with hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl or cyano substituted C 1-3 One or more substituents in the alkyl group are substituted; R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-8 Cycloalkyl, 3-10 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R 31 or R 32 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C containing 1-3 atoms selected from N, O or S 3-6 Cycloalkyl, 3-6 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-8 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 substituted with one or more substituents of a deuterated alkyl group; More preferably, R 31 or R 32 are each independently selected from deuterium, fluorine, chlorine, bromine, amino, methylamino, dimethylamino, hydroxyl, cyano, nitro, methyl, ethyl, isopropyl, fluoromethyl, fluoroethyl, difluoromethyl, difluoroethyl, trifluoromethyl, trifluoroethyl, cyclopropyl, cyclobutyl, cyclopentyl, aminomethyl, methoxy, ethoxy, propoxy, is substituted with one or more substituents; R x1 or R x2 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic group, C 6-10 Aryl or 5-10 membered heteroaryl, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 Preferably, R x1 or R x2 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxyl, cyano, nitro, C 1-3 Alkyl, C 2-3 Alkenyl, C 2-3 Alkynyl, C 1-3 Deuterated alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy, halogenated C 1-3 Alkoxy, C 1-3 Hydroxyalkyl, cyano substituted C 1-3 Alkyl, C 3-8 Cycloalkyl, 3-8 membered heterocyclic group containing 1-3 atoms selected from N, O or S, C 6-10 Aryl or 5-10 membered heteroaryl containing 1-3 atoms selected from N, O or S, optionally substituted by hydrogen, deuterium, hydroxyl, halogen, cyano, amino, C 1-3 Alkyl, C 1-3 Haloalkyl or C 1-3 More preferably, R x1 or R x2 Each is independently selected from hydrogen, deuterium, hydroxy, halogen, cyano, amino, methyl, ethyl, propyl or isopropyl.
8. The compound according to any one of claims 1 to 7, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that: Selected from the following compounds:
9. A pharmaceutical composition comprising a therapeutically effective dose of a compound of the general formula as shown in any one of claims 1 to 8, a stereoisomer thereof or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients.
10. Use of the compound of any one of claims 1 to 8, its stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 9 in the preparation of a medicament for treating a disease associated with PI3Kα; the PI3Kα-associated disease is selected from cancer, PROS, immune disorders or inflammatory disorders; further, the PROS is selected from vascular malformations, lymphatic malformations and megalencephaly, and the cancer is selected from gastric cancer, breast cancer, prostate cancer, lung cancer, liver cancer, bone cancer, brain cancer, head and neck cancer, intestinal cancer, pancreatic cancer, bladder cancer, testicular cancer, ovarian cancer, endometrial cancer and multiple myeloma; preferably clear cell ovarian cancer or breast cancer.
